fluoromisonidazole has been researched along with misonidazole in 307 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (2.28) | 18.7374 |
| 1990's | 29 (9.45) | 18.2507 |
| 2000's | 79 (25.73) | 29.6817 |
| 2010's | 169 (55.05) | 24.3611 |
| 2020's | 23 (7.49) | 2.80 |
| Authors | Studies |
|---|---|
| Budinger, TF; Gilbert, JC; Mathis, CA; Prados, MD; Valk, PE | 1 |
| Caldwell, JH; Casciari, JJ; Cowan, MJ; Graham, MM; Grierson, JR; Krohn, KA; Kroll, K; Lewellen, TK; Martin, GV; Rasey, JS | 1 |
| Hotchkiss, RS; Karl, IE | 1 |
| Grunbaum, Z; Krohn, KH; Prekeges, JL; Rasey, JS | 1 |
| Dence, CS; Hotchkiss, RS; Hwang, DR; Karl, IE; Rust, RS; Song, SK; Wasserman, TH; Welch, MJ | 1 |
| Chin, L; Evans, ML; Grunbaum, Z; Nelson, NJ; Rasey, JS | 1 |
| Caldwell, JH; Cerqueira, MD; Embree, L; Krohn, KA; Martin, GV; Rasey, JS | 1 |
| Bergmann, SR; Dence, CS; Herrero, P; Hwang, DR; Shelton, ME; Welch, MJ | 1 |
| Bonasera, TA; Dence, CS; Hwang, DR; Welch, MJ | 1 |
| Griffiths, JR; Maxwell, RJ; Workman, P | 1 |
| Dischino, DD; Jerabek, PA; Kilbourn, MR; Patrick, TB; Welch, MJ | 1 |
| Jerabek, PA; Kilbourn, MR; Krohn, KA; Mathias, CJ; Patrick, TB; Raichle, ME; Rasey, JS; Shaw, DW; Welch, MJ | 1 |
| Durand, RE; Grunbaum, Z; Krohn, KA; Magee, S; Nelson, NJ; Olive, PL; Rasey, JS | 1 |
| Sinesi, MS; Stone, HB | 1 |
| Rofstad, EK | 1 |
| Casciari, JJ; Graham, MM; Rasey, JS | 1 |
| Caldwell, JH; Johnson, PM; Krohn, KA; Martin, GV; Rasey, JS; Revenaugh, JR | 1 |
| Bergman, KS; Evans, ML; Graham, MM; Grierson, JR; Koh, WJ; Krohn, KA; Lewellen, TK; Lindsley, KL; Peterson, LM; Rasey, JS | 1 |
| Cherif, A; Gretzer, MB; Kim, EE; Li, C; Podoloff, DA; Wallace, S; Yang, DJ | 1 |
| Casciari, JJ; Rasey, JS | 1 |
| Cherif, A; Kim, EE; Tansey, W; Wallace, S; Yang, DJ | 1 |
| Berridge, MS; Lim, JL | 1 |
| Dence, CS; McCarthy, TJ; Welch, MJ | 1 |
| Nunn, AD | 1 |
| Chang, CW; Chen, KY; Chou, KL; Liu, RS; Wu, LC; Yang, DJ; Yeh, SH; Yen, SH; Yu, TW | 1 |
| Chang, CP; Chang, CW; Chen, KY; Chou, KL; Chu, LS; Liu, RS; Lui, MT; Wu, LC; Yeh, SH; Yen, SH | 1 |
| Caldwell, JH; Evans, ML; Graham, MM; Koh, WJ; Krohn, KA; Link, JM; Peterson, LM; Rasey, JS | 1 |
| Cook, GJ; Fogelman, I | 1 |
| Abbott, DF; Bladin, CF; Chan, JG; Donnan, GA; Egan, GF; Hirano, T; McKay, WJ; Read, SJ; Sachinidis, JI; Scott, AM; Tochon-Danguy, HJ | 1 |
| Aldinger, P; Bares, R; Becker, G; Becker, HD; Dissmann, PD; Fischer, H; Lauchart, W; Machulla, H; Patt, M; Piert, M; Stahlschmidt, A | 1 |
| Fujibayashi, Y; Lewis, JS; McCarthy, DW; McCarthy, TJ; Welch, MJ | 1 |
| Higuchi, T; Ilgan, S; Kim, EE; Liu, CW; Oh, CS; Podoloff, DA; Yang, DJ; Zareneyrizi, F | 1 |
| Fukuda, H; Hori, K; Ido, T; Iwata, R; Kubota, K; Saito, S; Sato, K; Tada, M; Yamada, S | 1 |
| Chin, LK; Hofstrand, PD; Rasey, JS; Tewson, TJ | 1 |
| Avril, N; Schwaiger, M; Weber, WA | 1 |
| Abbott, DF; Bladin, CF; Donnan, GA; Egan, GF; Hirano, T; McKay, WJ; Read, SJ; Sachinidis, JI; Scott, AM; Tochon-Danguy, HJ | 1 |
| Casciari, JJ; Chin, LK; Graham, MM; Hofstrand, PD; Muzi, M; Rasey, JS | 1 |
| Abbott, DF; Bladin, CF; Chan, JG; Donnan, GA; Egan, GF; Hirano, T; Markus, R; McKay, WJ; Read, SJ; Sachinidis, JI; Scott, AM; Tochon-Danguy, HJ | 1 |
| Aldinger, P; Bares, R; Becker, G; Machulla, HJ; Piert, M; Winter, E | 1 |
| D'Costa, I; Fisher, R; Hart, R; Hicks, R; Hughes, P; Peters, L; Rischin, D; Sexton, M; von Roemeling, R | 1 |
| Chan, F; Chan, JG; Cher, L; Hall, C; Hill, J; Kaye, A; Sachinidis, JI; Scott, AM; Stylli, S; Tochon-Danguy, HJ | 1 |
| Donnan, GA; Hirano, T; Kazui, S; Markus, R; O'Keefe, GJ; Read, S; Reutens, DC; Sachinidis, JI; Scott, AM; Tochon-Danguy, HJ | 1 |
| Ando, K; Aoki, M; Furusawa, Y; Kuwabara, Y; Maeda, M; Masuda, K; Sasaki, S; Yamamoto, F | 1 |
| Bentzen, L; Grönroos, T; Hansen, SB; Horsman, MR; Keiding, S; Overgaard, J | 1 |
| Alber, M; Eschmann, SM; Machulla, HJ; Paulsen, F | 1 |
| Bruckner, JD; Chin, LK; Conrad, EU; Eary, JF; Grierson, JR; Hofstrand, PD; Krohn, KA; Peterson, LM; Rajendran, JG; Rasey, JS; Wilson, DC | 1 |
| Barthel, H; Dannenberg, C; Kluge, R; Kumar, P; Patt, M; Sabri, O; Seese, A; Sorger, D; Tannapfel, A; Wiebe, LI | 1 |
| Bentzen, L; Falborg, L; Hansen, SB; Keiding, S; Keller, J; Nielsen, OS; Nordsmark, M; Overgaard, J | 1 |
| Cai, S; Chapman, JD; Chen, Y; Finn, R; Gerweck, L; Humm, J; Larson, S; Ling, C; O'Donoghue, J; Ruan, S; Schneider, R; Wen, B; Zanzonico, P | 1 |
| Chambers, BR; Donnan, GA; Kazui, S; Markus, R; Read, S; Reutens, DC; Sachinidis, JI; Tochon-Danguy, HJ; Wright, P | 1 |
| Bentzen, L; Eskola, O; Grönroos, T; Haaparanta, M; Horsman, MR; Keiding, S; Marjamäki, P; Minn, H; Murata, R; Solin, O | 1 |
| Ackermann, U; Chen, M; Donnan, GA; Howells, DW; Levi, CR; Liberatore, GT; Porritt, MJ; Read, SJ; Sachinidis, JI; Saita, K; Spratt, NJ; Tochon-Danguy, HJ | 1 |
| Donnan, G; Kazui, S; Markus, R; Read, S; Reutens, D | 1 |
| Donnan, GA; Kazui, S; Markus, R; Pearce, DC; Read, S; Reutens, DC; Sachinidis, JI; Tochon-Danguy, HJ; Wright, P | 1 |
| Blasberg, R; Burgman, P; Cai, S; Finn, R; Gelovani, J; Li, GC; Ling, CC; O'donoghue, J; Serganova, I; Wen, B; Zanzonico, P | 1 |
| Büll, U; Coenen, HH; Dimartino, E; Eble, MJ; Gagel, B; Hamacher, K; Maneschi, P; Pinkawa, M; Reinartz, P; Stanzel, S; Westhofen, M; Zimny, M | 1 |
| Bormans, G; Dubois, L; Dupont, P; Flamen, P; Haustermans, K; Landuyt, W; Mortelmans, L; Verbeken, E; Vermaelen, P | 1 |
| Ametamey, SM; Bruehlmeier, M; Roelcke, U; Schubiger, PA | 1 |
| Beck, R; Kumar, P; Machulla, HJ; McEwan, AJ; Picchio, M; Piert, M; Reischl, G; Schwaiger, M; Wester, HJ; Wiebe, LI; Ziegler, S | 1 |
| Bares, R; Dittmann, H; Eschmann, SM; Machulla, HJ; Paulsen, F; Reimold, M; Reischl, G; Welz, S | 1 |
| Hicks, RJ; Leong, T; Lim-Joon, D; Loi, S; Mackay, J; Michael, M; Mitchell, P; Mukesh, B; Ngan, SY; Rischin, D; Zalcberg, J | 1 |
| Burgman, P; Burnazi, E; Cai, S; Finn, RD; Humm, JL; Lewis, JS; Ling, CC; O'Donoghue, JA; Pugachev, A; Ruan, S; Smith-Jones, P; Welch, MJ; Wen, B; Zanzonico, P | 1 |
| Alber, M; Eschmann, SM; Paulsen, F; Thorwarth, D | 3 |
| Cumming, P; Horsman, MR; Keiding, S; Munk, OL; Sørensen, M | 1 |
| Gan, M; Luo, L; Tang, G; Tang, X; Wang, M | 1 |
| Bolton, DM; Davis, ID; Foo, SS; Lawrentschuk, N; Murone, C; Poon, AM; Putra, LG; Scott, AM | 1 |
| Chi, DY; Gil, HS; Kang, SH; Kim, JY; Moon, DH; Mosdzianowski, C; Oh, SJ; Ryu, JS | 1 |
| Ametamey, SM; Honer, M; Schubiger, PA; Wyss, MT | 1 |
| Alber, M; Eschmann, SM; Paulsen, F; Scheiderbauer, J; Thorwarth, D | 1 |
| Campa, J; Finn, R; Forster, G; Humm, J; Larson, S; Ling, C; Polycarpe-Holman, D; Zanzonico, P | 1 |
| Berlangieri, SU; Cher, LM; Fabinyi, G; Hannah, A; Lawrentschuk, N; Murone, C; O'Keefe, GJ; Papenfuss, A; Ramdave, S; Sachinidis, JI; Scott, AM | 1 |
| Asadpour, B; Buell, U; Coenen, HH; Demirel, C; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Pinkawa, M; Piroth, M; Reinartz, P; Stanzel, S; Zimny, M | 1 |
| Ametamey, S; Honer, M; Jochum, W; Oehler, C; Pruschy, M; Riesterer, O | 1 |
| Ackerman, U; Donnan, GA; Howells, DW; Spratt, NJ; Tochon-Danguy, HJ | 1 |
| Buell, U; Coenen, HH; DiMartino, E; Eble, M; Gagel, B; Hamacher, K; Reinartz, P; Westhofen, M; Zimny, M | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, M; Troost, EG; van der Kogel, AJ | 1 |
| Alber, M; Eschmann, SM; Holzner, F; Paulsen, F; Thorwarth, D | 1 |
| Blasberg, R; Humm, J; Ling, C; Serganova, I | 1 |
| Grierson, JR; Krohn, KA; Ng, P; O'Sullivan, J; Peterson, LM; Rajendran, JG; Scharnhorst, J; Schwartz, DL | 1 |
| Aigbirhio, FI; Baron, JC; Beech, JS; Clark, JC; Fryer, TD; Hong, YT; Hughes, JL; Igase, K; Jones, PS; Menon, DK; Smith, R; Takasawa, M | 1 |
| Brady, M; Kelly, CJ | 1 |
| Kaanders, JH; Oyen, WJ; Schinagl, DA | 1 |
| Padhani, A | 1 |
| Cherk, MH; Foo, SS; Knight, SR; Murone, C; O'Keefe, GJ; Papenfuss, AT; Poon, AM; Sachinidis, JI; Saunder, TH; Scott, AM | 1 |
| Bacharach, SL; Carson, J; Cook, JA; Eckelman, WC; English, S; Green, MV; Grimes, K; Krishna, MC; Matsumoto, K; Mitchell, JB; Seidel, J; Sowers, AL; Szajek, L | 1 |
| Chang, CW; Chen, CH; Chou, TK; Lin, WJ; Liu, RS; Wang, HE; Wang, SJ | 1 |
| Bergmann, R; Haase, C; Kampfrath, T; Mäding, P; Oswald, J; Pietzsch, J; Schwenzer, B; Treite, F | 1 |
| Asadpour, B; Coenen, HH; Demirel, C; DiMartino, E; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Maneschi, P; Pinkawa, M; Piroth, M; Reinartz, P; Scholbach, T; Stanzel, S; Zimny, M | 1 |
| Albo, F; Canu, N; Carunchio, I; Guatteo, E; Mercuri, NB; Pieri, M; Zona, C | 1 |
| Brader, P; Fong, Y; Hricak, H; Humm, JL; Ling, CC; Reid, V; Riedl, CC; Wen, B; Woo, Y; Zanzonico, P | 1 |
| Cai, S; Chan, K; Greco, C; Humm, JL; Lee, NY; Lin, Z; Ling, CC; Mechalakos, JG; Nehmeh, S; Schöder, H; Squire, OD; Zanzonico, PB | 1 |
| Lee, ST; Scott, AM | 1 |
| Erdi, YE; Greco, C; Humm, JL; Larson, SM; Lee, NY; Ling, CC; Mageras, G; Nehmeh, SA; Pham, HS; Schröder, H; Squire, O; Zanzonico, PB | 1 |
| Humm, J; Lee, N; Lin, Z; Ling, CC; Mechalakos, J; Nehmeh, S; Schoder, H | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, ME; Troost, EG; van der Kogel, AJ | 1 |
| Adamsen, TC; Krohn, KA; Link, JM; Muzi, M; O'Sullivan, F; Rajendran, JG; Rockhill, JK; Rostomily, RC; Silbergeld, DL; Spence, AM; Swanson, KR; Swanson, PE; Yagle, KJ | 1 |
| Krohn, KA; Yeuh, B | 1 |
| Cheguillaume, A; De Bast, M; de Groot, T; Gillart, J; Grégoire, V; Haustermans, K; Labar, D; Mahy, P | 1 |
| Haustermans, K; Lee, JA; Loeckx, D; Maes, F; Nuyts, J; Penninckx, F; Roels, S; Slagmolen, P; Stroobants, S | 1 |
| Dence, CS; Lewis, JS; Ponde, DE; Welch, MJ | 1 |
| Bol, A; Bormans, G; Cloetens, L; Dubois, L; Grégoire, V; Haustermans, K; Labar, D; Landuyt, W; Mortelmans, L; Nuyts, J | 1 |
| Chen, Q; Deng, X; He, F; Huang, Y; Li, GC; Ling, CC; Liu, Y; Minami, A; Sun, X; Wen, B; Xing, L; Zanzonico, PB | 1 |
| Adamsen, TC; Chakraborty, G; Harpold, HL; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Wang, CH | 1 |
| Chan, K; Fury, M; Humm, J; Lee, N; Ling, CC; Nehmeh, S; Schöder, H | 1 |
| Ackerstaff, E; Carlin, S; Cho, H; Humm, JL; Koutcher, JA; Ling, CC; Lupu, ME; O'Donoghue, J; Rizwan, A; Wang, Y; Zanzonico, PB | 1 |
| Chang, CH; Chang, CW; Chang, TJ; Chou, TK; Lin, WJ; Liu, RS; Wang, HE; Wang, SJ; Wu, CY | 1 |
| Alvord, EC; Chakraborty, G; Hadley, J; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Szeto, MD | 1 |
| Bal, M; Georgi, JC; Humm, JL; Lee, NY; Narayanan, M; Nehmeh, SA; O'Donoghue, J; Paulus, T; Schmidtlein, CR; Wang, W; Zanzonico, PB | 1 |
| Donnan, GA; Howells, DW; Spratt, NJ | 1 |
| Hu, M; Xie, P; Yu, JM | 1 |
| Ametamey, S; Dominietto, M; Honer, M; Keist, R; Kotevic, I; Lehmann, S; Rudin, M; Stiehl, DP; Wenger, RH; Wollenick, K | 1 |
| Czabanka, M; Denecke, T; Nagel, A; Plotkin, M; Sarrafzadeh, AS; Vajkoczy, P | 1 |
| Fury, MG; Humm, JL; Jansen, JF; Koutcher, JA; Lee, NY; Pfister, DG; Schöder, H; Shukla-Dave, A; Stambuk, HE; Wang, Y | 1 |
| Humm, JL; Ling, CC; Nehmeh, SA; Wang, K; Yorke, E | 1 |
| Chang, J; Fichtinger, G; Finn, RD; Kazanzides, P; Ling, CC; Wen, B; Zanzonico, P | 1 |
| Georgi, JC; Guillem, J; Humm, JL; Lee, NY; Narayanan, M; Schöder, H; Wang, W | 1 |
| Bradley, D; Dalah, E; Nisbet, A | 1 |
| Korde, A; Krishnamurthy, NV; Nandy, S; Rajan, MG | 1 |
| Kikuchi, M; Senda, M; Shinohara, S; Yamane, T | 1 |
| Abad, S; Fernández-Soriano, FJ; Figueiras, FP; Gispert, JD; Herance, JR; Jiménez, X; Pareto, D; Planas, AM; Popota, F; Rojas, S; Ruiz, A; Torrent, È | 1 |
| Ball, C; Bejot, R; Carroll, L; Elizarov, AM; Gouverneur, V; Hill, S; Kelly, C; Kersemans, V; King, RC; Kolb, HC; Miraghaie, R; Smart, S; Zhang, J | 1 |
| Haubner, R | 1 |
| Baron, JC; Beech, JS; Fryer, TD; Hong, YT; Smith, R | 1 |
| Bentzen, L; Buus, S; Keiding, S; Mortensen, LS; Munk, OL; Nordsmark, M; Overgaard, J | 1 |
| Donnan, GA; Howells, DW; McLeod, DD; Spratt, NJ | 1 |
| Bohn, P; Dubray, B; Edet-Sanson, A; Gardin, I; Hapdey, S; Ménard, JF; Modzelewski, R; Salles, A; Thiberville, L; Vera, P | 1 |
| Kawai, N; Kudomi, N; Maeda, Y; Miyake, K; Nishiyama, Y; Okada, M; Tamiya, T; Yamamoto, Y | 1 |
| Abolmaali, N; Baumann, M; Haase, R; Koch, A; Kotzerke, J; Steinbach, J; Zips, D; Zöphel, K | 1 |
| Carlin, S; Ling, CC; Lorenzen, S; O'Donoghue, JA; Oehler, C; Russell, J; Zanzonico, P | 1 |
| Alber, M; Kaanders, JH; Mönnich, D; Oyen, WJ; Thorwarth, D; Troost, EG | 2 |
| Conrad, EU; Eary, JF; Krohn, KA; Link, JM; Mankoff, DA; Muzi, M; White, JK | 1 |
| Alessio, AM; Alvord, EC; Anderson, AR; Chakraborty, G; Champley, K; Claridge, J; Gu, S; Kinahan, PE; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR | 1 |
| Honer, M; Krämer, SD; Liu, Y; Raina, S; Segerer, S; Serra, AL; Wang, X; Wüthrich, RP | 1 |
| Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C | 1 |
| Fujiwara, K; Hori, SY; Kikuchi, M; Naito, Y; Senda, M; Shinohara, S; Tona, Y; Yamane, T; Yamazaki, H | 1 |
| Blower, PJ; Handley, MG; Medina, RA; Nagel, E; Southworth, R | 1 |
| Bentzen, SM; Bowen, SR; Jeraj, R; Nordsmark, M; van der Kogel, AJ | 1 |
| Barré, L; Bernaudin, M; Delamare, J; Divoux, D; Marteau, L; Petit, E; Roussel, S; Sobrio, F; Toutain, J; Valable, S | 1 |
| Hendrickson, K; Krohn, K; Peterson, L; Phillips, M; Rajendran, J; Smith, W | 1 |
| Kong, FM; Meng, X; Yu, J | 1 |
| De Clermont, H; Fernandez, P; Huchet, A; Lamare, F; Rivière, A | 1 |
| Allen, PD; Cornelissen, B; Dilworth, JR; Falzone, N; Gouverneur, V; Hill, SA; Hueting, R; Hussien, K; Kersemans, V; Muschel, RJ; Smart, SC; Tredwell, M | 1 |
| Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S | 1 |
| Barbet, J; Bourgeois, M; Cherel, M; Faivre-Chauvet, A; Guerard, F; Michel, N; Mougin-Degraef, M; Rajerison, H | 1 |
| Hattori, N; Hirata, K; Houkin, K; Kobayashi, H; Kuge, Y; Magota, K; Shiga, T; Tamaki, N; Tanaka, S; Terasaka, S; Yamaguchi, S | 1 |
| Clemenceau, S; Ferrand, R; Feuvret, L; George, B; Habrand, JL; Kerrou, K; Lot, G; Mammar, H; Mazure, N; Mokhtari, K; Nataf, V; Polivka, M; Pontvert, D; Pouysségur, J; Talbot, JN | 1 |
| Aga, F; Kawai, N; Kudomi, N; Maeda, Y; Nishiyama, Y; Ono, Y; Yamamoto, Y | 1 |
| Katoh, N; Kuge, Y; Okamoto, S; Onimaru, R; Shiga, T; Shirato, H; Suzuki, R; Takeuchi, W; Tamaki, N; Tsuchiya, K; Yasuda, K | 1 |
| Ayers, GD; Fluckiger, JU; Peterson, TE; Tantawy, MN; Whisenant, JG; Yankeelov, TE | 1 |
| Cheeseman, C; Khlebnikov, V; Kumar, P; Liang, H; Shustov, G; Wiebe, LI; Yang, XH; Zheng, W | 1 |
| Adamsen, TCh; de Carvalho Patricio, BF; de Souza Albernaz, M; Reynaud, F; Santos-Oliveira, R; Weissmuller, G | 1 |
| Chen, L; Guan, Y; Kolb, HC; Walsh, JC; Zhang, J; Zhang, Z | 1 |
| Deng, A; Du, J; Qiao, J; Yin, W; Zhou, X; Zhu, L | 1 |
| Ball, CE; Elizarov, A; Kolb, H; Lebedev, A; Leece, AK; Mahmood, U; Miraghaie, R; Yokell, DL; Zhang, J | 1 |
| Bartlett, RM; Beattie, BJ; Carlin, SD; Chen, Q; Fischer, A; Georgi, JC; Gonen, M; Humm, JL; Naryanan, M; O'Donoghue, J; Roble, G; Zanzonico, PB | 1 |
| Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y | 1 |
| Askoxylakis, V; Bischof, M; Debus, J; Dimitrakopoulou-Strauss, A; Dinkel, J; Eichinger, M; Haberkorn, U; Huber, PE; Kopp-Schneider, A; Sommer, G; Stieltjes, B; Strauss, LG; Thieke, C | 1 |
| Abolmaali, N; Abramyuk, A; Appold, S; Baumann, M; Haase, R; Kotzerke, J; Perrin, R; Steinbach, J; Zips, D; Zöphel, K | 1 |
| Campbell, EM; Ee, H; Francis, RJ; Morandeau, L; Robins, PD; Segard, T; Yusoff, IF | 1 |
| Colletti, PM; Fanti, S; Nanni, C; Rubello, D | 1 |
| Dierckx, RA; Halmos, GB; Langedijk, JA; Pruim, J; Roodenburg, JL; van der Laan, BF; Wedman, J | 1 |
| Anderson, NJ; Chang, JH; Gan, HK; Gong, SJ; Gunawardana, DH; Khoo, V; Lee, ST; Lim Joon, D; O'Keefe, G; Sachinidis, J; Scott, AM; Wada, M | 1 |
| Ito, YM; Kasai, K; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Shirato, H; Tamaki, N; Yasuda, K | 1 |
| Hanzawa, H; Hatano, T; Kuge, Y; Kuno, N; Nishijima, K; Sakamoto, T; Tamaki, N; Zhao, S; Zhao, Y | 1 |
| Barré, L; Bernaudin, M; Corroyer-Dulmont, A; Divoux, D; Durand, L; MacKenzie, ET; Marteau, L; Pérès, EA; Petit, E; Roussel, S; Toutain, J; Valable, S | 1 |
| Cheng, J; Lei, L; Liu, G; Pan, L; Shao, Z; Sun, Y; Wang, X; Xu, J; Zhang, Y | 1 |
| Hata, H; Kitagawa, Y; Kuge, Y; Okamoto, S; Sato, J; Shiga, T; Shindoh, M; Tamaki, N; Yamazaki, Y | 1 |
| Ametamey, SM; Arlt, MJ; Born, W; Brennecke, P; Campanile, C; Fischer, CR; Fuchs, B; Gvozdenovic, A; Honer, M; Krämer, SD; Müller, A; Sabile, AA; Schibli, R | 1 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Mix, M; Weber, WA; Wiedenmann, N | 1 |
| Aide, N; Berriolo-Riedinger, A; Blagosklonov, O; Brenot-Rossi, I; Bridji, B; Cachin, F; Caignon, JM; Chaumet-Riffaud, P; Collombier, L; Courbon, F; Devillers, A; Doyeux, K; Dubray, B; Fernandez, P; Gremillet, E; Houzard, C; Kolesnikov-Gauthier, H; Modzelewski, R; Olivier, P; Roux, J; Tessonnier, L; Thureau, S; Vera, P; Vervueren, L | 1 |
| Alber, M; Kaanders, JH; Mönnich, D; Oyen, WJ; Thorwarth, D; Troost, EG; Zips, D | 1 |
| Haba, R; Hoshikawa, H; Iwasaki, A; Kudomi, N; Maeda, Y; Matsunaga, T; Nishiyama, Y; Norikane, T; Yamamoto, Y | 1 |
| Aigbirhio, FI; Alawneh, JA; Baron, JC; Carpenter, TA; Fryer, TD; Jensen-Kondering, U; Jones, PS; Marrapu, ST; Morris, RS; Moustafa, RR; Warburton, EA | 1 |
| Hirata, K; Houkin, K; Kobayashi, H; Shiga, T; Terasaka, S; Yamaguchi, S | 1 |
| de Clermont-Gallerande, H; Fernandez, P; Hatt, M; Henriques de Figueiredo, B; Lamare, F; Merlin, T; Vimont, D | 1 |
| Carson, RE; Chan, C; Fung, EK; Jin, X; Liu, C; Mulnix, T; Naganawa, M | 1 |
| Hyun, JS; Lee, SJ; Oh, SJ; Ryu, JS; Yu, KH | 1 |
| Astner, ST; Bayer, C; Cheng, X; Maftei, CA; Shi, K; Vaupel, P; Ziegler, SI | 1 |
| Gambrell, JV; Mistry, N; Quarles, CC; Stokes, AM | 1 |
| Badimon, JJ; Fayad, ZA; Fuster, V; Izquierdo-Garcia, D; Mateo, J | 1 |
| Baumann, M; Bergmann, R; Beuthien-Baumann, B; Brüchner, K; Hessel, F; Kotzerke, J; Krause, M; Mosch, B; Schütze, C; Steinbach, J; Thames, H; Yaromina, A; Zips, D | 1 |
| Cao, WD; Haba, R; Kawai, N; Lin, W; Maeda, Y; Miyake, K; Nishiyama, Y; Ogawa, D; Tamiya, T; Yamamoto, Y | 1 |
| Asaka, T; Hata, H; Kitagawa, Y; Kuge, Y; Miyakoshi, M; Okamoto, S; Sato, J; Shiga, T; Shindoh, M; Tamaki, N; Yamazaki, Y | 1 |
| Bell, C; Dowson, N; Fay, M; Gal, Y; Jeffree, RL; Pagnozzi, A; Poole, CM; Puttick, S; Rose, S; Thomas, P | 1 |
| Nardo, L; Pampaloni, MH | 1 |
| Giraud, P; Servagi-Vernat, S | 1 |
| Fatema, CN; Kitagawa, Y; Kuge, Y; Nishijima, K; Tamaki, N; Yasuda, K; Yu, W; Zhao, S; Zhao, Y | 1 |
| Benech, J; De Clermont-Gallerande, H; De Mones del Pujol, E; Digue, L; Fernandez, P; Galland-Girodet, S; Hatt, M; Henriques de Figueiredo, B; Lamare, F; Zacharatou, C | 1 |
| Dubois, L; Eriksson, J; Lambin, P; Lieuwes, NG; Peeters, SG; van Dongen, GA; van Elmpt, W; Zegers, CM | 1 |
| Chen, YL; Cheney, MD; DeLaney, TF; Depauw, N; Grosu, AL; Hornicek, FJ; Lim, R; Schwab, JH; Shih, HA; Trofimov, AV; Winrich, BK | 1 |
| Hawkins-Daarud, AJ; Hendrickson, K; Jacobs, J; Kinahan, P; Krohn, KA; Mrugala, MM; Neal, ML; Rockhill, JK; Rockne, RC; Swanson, KR; Trister, AD | 1 |
| Banerjee, S; Mallia, MB; Mathur, A; Sarma, HD | 1 |
| Hansen, AE; Jensen, AI; Jørgensen, JT; Kjær, A; Revunov, E; Severin, GW; Zhuravlev, F | 1 |
| Bell, C; Dowson, N; Fay, M; Gal, Y; Puttick, S; Rose, S; Thomas, P | 1 |
| Krohn, KA; Rajendran, JG | 1 |
| Arvold, ND; Heidari, P; Kunawudhi, A; Mahmood, U; Sequist, LV | 1 |
| Akula, MR; Bois, F; Carlson, DJ; Collier, L; Hammond, K; Huang, Y; Kabalka, GW; Kelada, OJ; Ropchan, J; Zheng, MQ | 1 |
| Bezak, E; Jennings, M; Marcu, LG | 1 |
| Ai, H; Chen, S; Cheng, Z; Jiang, X; Li, X; Lu, H; Qing, H; Wei, R; Wu, C; Xu, G | 1 |
| Galoforo, S; Grills, IS; Kane, JL; Krueger, SA; Marples, B; Wilson, GD; Wobb, J | 1 |
| Fink, JR; Krohn, KA; Mankoff, DA; McLaughlin, LJ; Muzi, JP; Muzi, M; O'Sullivan, JN; Peterson, LM; Rajendran, JG | 1 |
| Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B | 1 |
| Mönnich, D; Thorwarth, D; Troost, EG; van Elmpt, W; Wack, LJ; Zegers, CM; Zips, D | 1 |
| Francis, RJ; Lee, YC; Millward, MJ; Morandeau, L; Nowak, AK; Segal, A; Segard, T | 1 |
| Bradley, KM; Fenwick, JD; Gleeson, FV; Higgins, GS; Macpherson, RE; McGowan, DR | 1 |
| Cui, YL; Li, XF; Wang, X | 1 |
| Hamaji, M; Harada, H; Kimura, H; Koizumi, K; Koyasu, S; Nakamoto, Y; Nobashi, T; Sano, K; Togashi, K; Tsuji, Y | 1 |
| Abolmaali, N; Appold, S; Baumann, M; Gudziol, V; Haase, R; Kotzerke, J; Krause, M; Perrin, R; Richter, C; Steinbach, J; Stützer, K; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Mix, M; Nestle, U; Pfeiffer, J; Vach, W; Weber, WA; Wiedenmann, NE | 1 |
| la Fougère, C; Mauz, PS; Mönnich, D; Nikolaou, K; Pfannenberg, C; Reischl, G; Thorwarth, D; Welz, S; Zips, D | 1 |
| Hirata, K; Tamaki, N | 1 |
| Higashino, K; Kuge, Y; Masaki, Y; Nishijima, K; Numata, Y; Sakamoto, S; Shimizu, Y; Tamaki, N; Tanaka, Y; Yamaguchi, Y; Yoshioka, T; Zhao, S | 1 |
| Carlin, SD; Gönen, M; Grkovski, M; Humm, JL; Lee, NY; Nehmeh, SA; Schöder, H; Schwartz, J; Zanzonico, PB | 1 |
| Adamsen, TC; Arteaga-Marrero, N; Brekke Rygh, C; Lutay, N; Mainou-Gomez, JF; Olsen, DR; Reed, RK | 1 |
| De Bruycker, S; Pauwels, P; Staelens, S; Stroobants, S; Van den Wyngaert, T; Vangestel, C; Wouters, A; Wyffels, L | 1 |
| Yoshimoto, M | 1 |
| Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML | 1 |
| Hatanaka, KC; Hirata, K; Kobayashi, H; Kobayashi, K; Kuge, Y; Manabe, O; Shiga, T; Tamaki, N; Terasaka, S; Toyonaga, T; Watanabe, S; Yamaguchi, S; Yuzawa, S | 1 |
| Carson, RE; Chan, C; Gallezot, JD; Germino, M; Kelada, OJ; Liu, C; Liu, Y; Ma, T; Naganawa, M; Sinusas, AJ; Yu, Y | 1 |
| Wang, H; Xu, H; Xue, Y; Yu, W; Zhang, Y; Zhao, X | 1 |
| Aigbirhio, FI; Carter, EL; Coles, JP; Fryer, TD; Gee, GS; Geeraerts, T; Grossac, J; Hong, YT; Lupson, V; Menon, DK; Newcombe, VF; Outtrim, J; Smith, R; Veenith, TV | 1 |
| Hirata, K; Kikuchi, H; Kobayashi, K; Manabe, O; Oyama-Manabe, N; Shiga, T; Shozo, O; Tamaki, N; Toyonaga, T; Uchiyama, Y; Watanabe, S | 1 |
| Andrzejewski, P; Baltzer, P; Georg, D; Georg, P; Grimm, C; Helbich, TH; Karanikas, G; Mitterhauser, M; Pinker, K; Poetter, R; Polanec, SH; Polterauer, S; Sturdza, A; Wadsak, W | 1 |
| Barboriak, DP; Eikman, EA; Ellingson, BM; Fink, JR; Gerstner, ER; Greco, E; Hanna, L; Kostakoglu, L; Mankoff, DA; Mintz, A; Muzi, M; Prah, M; Ratai, EM; Schmainda, KM; Sorensen, AG; Zhang, Z | 1 |
| Hirata, K; Kasai, K; Kuge, Y; Magota, K; Nishijima, KI; Okamoto, S; Onimaru, R; Shiga, T; Shirato, H; Tamaki, N; Tuchiya, K; Watanabe, S; Yasuda, K | 1 |
| Hu, X; Huang, Y; Wang, S; Wei, Y; Yu, J; Yu, Q; Yuan, S; Zhao, S; Zhao, W; Zhu, S | 1 |
| Baumann, M; Mönnich, D; Thorwarth, D; Wack, LJ; Yaromina, A; Zips, D | 1 |
| Barnes, SL; Kang, H; Quarles, CC; Sanchez, V; Sorace, AG; Syed, AK; Yankeelov, TE | 1 |
| Baxi, S; Beattie, B; Boyle, J; Chan, S; Ganly, I; Humm, J; Katabi, N; Lanning, R; Lee, N; Li, D; McBride, S; Mitrani, L; Morris, LG; Pfister, DG; Riaz, N; Schoder, H; Sherman, E; Wong, R; Yarusi, B; Zhang, Z | 1 |
| Shi, K; Vaupel, P; Ziegler, SI | 1 |
| Chen, X; Jacobson, O; Kiesewetter, DO; Niu, G; Srivatsan, A; Tong, X; Wang, Y; Wang, Z; Yang, X; Zheng, H | 1 |
| Anzellotti, AI; Frank, JE; Hillesheim, DA; Khachaturian, MH; Merrill, JR; Yuan, H | 2 |
| Bittner, MI; Bucher, S; Grosu, AL; Hentschel, M; Kayser, G; Meyer, PT; Mix, M; Rücker, G; Weber, WA; Werner, M; Wiedenmann, N | 1 |
| Hattori, N; Hirata, K; Ito, YM; Kobayashi, H; Kobayashi, K; Kuge, Y; Manabe, O; Shiga, T; Tamaki, N; Tanaka, S; Terasaka, S; Toyonaga, T; Watanabe, S; Yamaguchi, S | 1 |
| Partridge, M; Warren, DR | 1 |
| Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Kobayashi, K; Motegi, H; Shiga, T; Tamaki, N; Terasaka, S; Toyonaga, T; Yamaguchi, S | 1 |
| Astner, ST; Bayer, C; Gaertner, FC; Nüsslin, F; Shi, K; Vaupel, P; Wilkens, JJ; Ziegler, SI | 1 |
| Beattie, BJ; Carlin, SD; Grkovski, M; Humm, JL; Lee, NY; Leeman, JE; O'Donoghue, JA; Riaz, N; Schöder, H | 2 |
| Bueno, MJ; Mouron, S; Quintela-Fandino, M | 1 |
| Barré, L; Bekaert, L; Bernaudin, M; Bordji, K; Branger, P; Collet, S; Constans, JM; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Manrique, A; Petit, E; Ponte, K; Valable, S | 1 |
| Fougère, C; Leibfarth, S; Nikolaou, K; Pfannenberg, C; Reischl, G; Schmidt, H; Schwenzer, N; Simoncic, U; Thorwarth, D; Welz, S; Zips, D | 1 |
| Booth, CJ; Carlson, DJ; Carson, RE; Decker, RH; Huang, Y; Kelada, OJ; Liu, Y; Oelfke, U; Rockwell, S; Zheng, MQ | 1 |
| Aigbirhio, FI; Baron, JC; Carpenter, TA; Ejaz, S; Fryer, TD; Jensen-Kondering, U; Manavaki, R; Sawiak, SJ; Williamson, DJ | 1 |
| Hatazawa, J; Hiraka, T; Hosoya, T; Kanoto, M; Kirii, K; Matsuda, K; Sakurada, K; Sonoda, Y; Sugai, Y; Toyoguchi, Y | 1 |
| Grimes, DR; Warren, DR; Warren, S | 1 |
| Hirata, K; Nagara, T; Shiga, T; Toyonaga, T | 1 |
| Fenwick, JD; Gleeson, FV; Hackett, SL; Higgins, GS; Liu, D; Macpherson, RE; McGowan, DR; McKenna, WG | 1 |
| Higashino, K; Kuge, Y; Masaki, Y; Nishijima, KI; Numata, Y; Shimizu, Y; Tamaki, N; Yoshioka, T; Zhao, S | 1 |
| Asaka, T; Hirata, K; Kitagawa, Y; Kuge, Y; Ohga, N; Okamoto, S; Sato, J; Shiga, T; Shindoh, M; Tamaki, N; Watanabe, S | 1 |
| Al Jaberi, M; Förster, S; Gempt, J; Göttler, J; Kluge, A; Lukas, M; Meyer, B; Preibisch, C; Pyka, T; Ringel, F; Schlegel, J; Shi, K; Wiestler, B; Zimmer, C | 1 |
| Bandurska-Luque, A; Baumann, M; Kotzerke, J; Krause, M; Löck, S; Perrin, R; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Barré, L; Bernaudin, M; Chakhoyan, A; Collet, S; Constans, JM; Delcroix, N; Guillamo, JS; Kauffmann, F; Lechapt-Zalcman, E; MacKenzie, ET; Petit, E; Touzani, O; Valable, S | 1 |
| Ito, YM; Kuge, Y; Nishikawa, Y; Okamoto, S; Onimaru, R; Peng, H; Shiga, T; Shirato, H; Takeuchi, W; Tamaki, N; Tsuchiya, K; Watanabe, S; Yasuda, K | 1 |
| Fu, M; Lv, B; Qiu, J; Wang, X; Zheng, X; Zhuo, W | 1 |
| Asaka, T; Hirata, K; Kitagawa, Y; Ohga, N; Sato, J; Satoh, A; Shiga, T; Tamaki, N; Watanabe, S | 1 |
| Aigbirhio, FI; Baron, JC; Ejaz, S; Fryer, TD; Hong, YT; Jensen-Kondering, U; Sawiak, SJ; Sitnikov, S; Williamson, DJ | 1 |
| Balcerzyk, M; Civantos-Jubera, G; Egea-Guerrero, JJ; Fernandez-Gomez, I; Fernandez-Maza, L; Gordillo-Escobar, E; Murillo-Cabezas, F; Parrado-Gallego, A; Vilches-Arenas, A | 1 |
| Apte, A; Crispin-Ortuzar, M; Deasy, JO; Grkovski, M; Humm, JL; Lee, NY; Oh, JH; Schöder, H | 1 |
| Asgari, H; Sefidgar, M; Soltani, M | 1 |
| Fukuda, K; Hanaoka, K; Hosono, M; Inada, M; Ishikawa, K; Kanamori, S; Nakamatsu, K; Nishimura, Y; Tachibana, I; Tatebe, H | 1 |
| Huang, Y; Li, L; Liu, W; Lu, H; Wei, Y; Yu, J; Yu, Q; Yuan, S; Zhao, S; Zheng, J | 1 |
| Dong, M; Guo, S; Han, X; Li, G; Li, H; Lin, Y; Mi, Y; Ruan, Q; Wang, B; Xu, D; Zhang, X | 1 |
| Buchegger, F; De Perrot, T; Garibotto, V; Mainta, IC; Miralbell, R; Tille, JC; Vallée, JP; Zilli, T | 1 |
| Andronesi, OC; Barboriak, D; Ellingson, B; Fink, J; Gerstner, ER; Greco, E; Hanna, L; Kim, D; Kostakoglu, L; Mankoff, D; Mintz, A; Muzi, M; Prah, M; Ratai, EM; Richards, T; Schmainda, K; Sorensen, G; Zhang, Z | 1 |
| Agarwal, J; Budrukkar, A; Chatterjee, A; Ghosh-Laskar, S; Gupta, T; Kunder, S; Murthy, V; Purandare, N; Rangarajan, V | 1 |
| Asano, A; Hasebe, T; Hirokawa, E; Kuji, I; Osaki, A; Saeki, T; Shimada, H; Sugitani, I; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Baltas, D; Bunea, H; Dasu, A; Grosu, AL; Lazzeroni, M; Toma-Dasu, I | 1 |
| Abolmaali, N; Appold, S; Bandurska-Luque, A; Baumann, M; Haase, R; Kotzerke, J; Krause, M; Löck, S; Richter, C; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K | 1 |
| Shimizu, Y | 1 |
| Sorace, AG; Syed, AK; Whisenant, JG; Woodall, R; Yankeelov, TE | 1 |
| Kuge, Y; Motomura, A; Ogawa, M; Shimizu, Y; Takakura, H; Tamaki, N | 1 |
| Gafita, A; Hirata, K; Kroenke, M; Kuge, Y; Magota, K; Okamoto, S; Shiga, T; Tamaki, N; Watanabe, S | 1 |
| Kiriu, M; Kuge, Y; Matsumoto, H; Nakata, N; Nishijima, KI; Okumura, Y; Shiga, T; Tamaki, N; Zhao, S | 1 |
| Jiang, H; Jiang, HJ; Li, X; Pan, WB; Wang, YQ; Xu, HL; Zhang, MY; Zhang, RJ | 1 |
| Cegla, P; Joanna, K; Julian, M; Michal, S; Sebastian, G; Witold, C | 1 |
| Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA | 1 |
| Aust, DE; Bandurska-Luque, A; Baretton, GB; Baumann, M; Buchholz, F; Gudziol, V; Kotzerke, J; Krause, M; Linge, A; Löck, S; Nowak, A; Overgaard, J; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K | 1 |
| Fuchs, K; Gonzalez-Menendez, I; Guenthoer, P; Kneilling, M; Laufer, S; Pichler, BJ; Quintanilla-Martinez, L; Reischl, G | 1 |
| Abdo, RA; Bentourkia, M; Fernandez, P; Lamare, F | 1 |
| Furuya, S; Hirata, K; Kobayashi, H; Kobayashi, K; Kudo, K; Kuge, Y; Magota, K; Manabe, O; Shiga, T; Tamaki, N; Terasaka, S; Toyonaga, T; Yamaguchi, S | 1 |
| Bak, B; Cegła, P; Cholewinski, W; Kazmierska, J; Malicki, J; Piotrowski, T; Sowinska, A | 1 |
| Calderoni, L; Castellucci, P; Fanti, S; Telo, S; Vichi, S; Zagni, F | 1 |
| Baltas, D; Bunea, H; Grosu, AL; Lazzeroni, M; Mix, M; Schiavo, F; Sörensen, A; Stoykow, C; Thomann, B; Toma-Dasu, I; Ureba, A; Wiedenmann, N | 1 |
| Fujima, N; Hirata, K; Kudo, K; Minowa, K; Shima, T; Yamano, S | 1 |
| Baell, JB; Davis, TP; Davydova, M; Goos, JACM; Greguric, I; Lengkeek, N; Lewis, JS; Quinn, JF; Whittaker, MR | 1 |
| Baumann, M; Boeke, S; Gregoire, V; Hofheinz, F; Johansen, J; Krause, M; Löck, S; Mönnich, D; Overgaard, J; Saksø Mortensen, L; Saksø, M; Seidlitz, A; Skripcak, T; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S | 1 |
| Arnberg, F; Holmin, S; Ingemann Jensen, A; Jussing, E; Little, PV; Lu, L; Mitsios, N; Mulder, J; Tran, TA | 1 |
| Cheon, GJ; Kang, SY; Lee, KH; Oh, DY; Yoon, J | 1 |
| Mitamura, K; Nishiyama, Y; Norikane, T; Takata, T; Yamamoto, Y | 1 |
| Fuentes, A; Healey, DR; Kodibagkar, VD; Quarles, CC; Scarpelli, ML | 1 |
| Andreev, DN; Bellaye, PS; Bonniaud, P; Bouchard, A; Cochet, A; Collin, B; Frenay, J; Goirand, F; Guillemin, M; Helbling, A; Kucheryavy, YA; Mayev, IV; Moreau, M; Mothes, C; Oudot, A; Tanguy, J | 1 |
| Brenner, AJ; Clarke, GD; Floyd, JR; Fox, PT; Huang, S; Hyun, H; Jerabek, PA; Lee, EQ; Michalek, JE; Muzi, M; Reardon, DA; Schmainda, KM; Wen, PY | 1 |
| Bernaudin, M; Berro, DH; Chakhoyan, A; Collet, S; Constans, JM; Derlon, JM; Guillamo, JS; Guillouet, S; Hatt, M; Lechapt-Zalcman, E; Perrio, C; Valable, S; Visvikis, D | 1 |
| Bogni, A; Casanova, C; Cucchi, C; Pascali, C; Seregni, E | 1 |
| Angermeier, A; Della Manna, D; Larimer, BM; Li, Y; Reeves, KM; Song, PN; Sorace, AG; Wang, J; Yang, ES | 1 |
| Alber, M; Belka, C; La Fougère, C; Nikolaou, K; Paulsen, F; Pfannenberg, C; Reimold, M; Reischl, G; Thorwarth, D; Welz, S; Zips, D | 1 |
| Pacella, S | 1 |
| Qin, J; Tang, Y; Wang, B | 1 |
| Barbier, EL; Bernaudin, M; Chakhoyan, A; Chazalviel, L; Corroyer-Dulmont, A; Divoux, D; Guillouet, S; Toutain, J; Touzani, O; Valable, S | 1 |
| Bourigault, P; Higgins, GS; Macpherson, RE; McGowan, DR; Skwarski, M | 1 |
| Arakawa, Y; Fushimi, Y; Nakamoto, Y; Sakata, A; Shimizu, Y | 1 |
| Boeke, S; Bowden, G; Cotton, J; Krueger, MA; Leibfarth, S; Pichler, BJ; Thorwarth, D; Winter, RM; Zips, D | 1 |
26 review(s) available for fluoromisonidazole and misonidazole
| Article | Year |
|---|---|
Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis.
Topics: Acidosis, Lactic; Animals; Blood Gas Analysis; Cell Hypoxia; Energy Metabolism; Fluorine Radioisotopes; Humans; Lactates; Lactic Acid; Magnetic Resonance Spectroscopy; Misonidazole; Oxygen Consumption; Sepsis | 1992 |
Relevance of positron emission tomography (PET) in oncology.
Topics: Carbon Radioisotopes; Fluorides; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Methionine; Misonidazole; Neoplasm Staging; Neoplasms; Radioisotopes; Radiopharmaceuticals; Sensitivity and Specificity; Thymidine; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Tumor hypoxia imaging.
Topics: Biomarkers; Cell Hypoxia; Fluorodeoxyglucose F18; Humans; Misonidazole; Models, Biological; Neoplasm Metastasis; Neoplasms; Oxygen; Positron-Emission Tomography | 2006 |
PET imaging of tumour hypoxia.
Topics: Cell Hypoxia; Coordination Complexes; Humans; Magnetic Resonance Imaging; Misonidazole; Neoplasms; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones | 2006 |
Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.
Topics: Animals; Brain Ischemia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Fluorine Radioisotopes; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Misonidazole; Myocardial Ischemia; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stroke | 2007 |
Novel imaging approaches to head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Diagnostic Imaging; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Oxygen; Positron-Emission Tomography | 2008 |
[Advances in research on hypoxic imaging in cancer radiotherapy].
Topics: Cell Hypoxia; Humans; Misonidazole; Neoplasms; Positron-Emission Tomography; Radiography; Radiotherapy, Intensity-Modulated | 2009 |
PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.
Topics: Amino Acids; Biological Transport; Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Humans; Lipid Metabolism; Misonidazole; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin | 2010 |
PET imaging of cardiac hypoxia: opportunities and challenges.
Topics: Acidosis; Animals; Copper; Copper Radioisotopes; Coronary Artery Disease; Coronary Circulation; Humans; Hypoxia; Misonidazole; Myocardial Ischemia; Myocardium; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Rats; Reducing Agents; Sensitivity and Specificity; Thiosemicarbazones; Tissue Distribution | 2011 |
Implementation of hypoxia measurement into lung cancer therapy.
Topics: Cell Hypoxia; Humans; Lung Neoplasms; Misonidazole; Oxygen; Positron-Emission Tomography; Prognosis; Radiosurgery | 2012 |
Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review.
Topics: Cell Hypoxia; Coordination Complexes; Copper Radioisotopes; Humans; Misonidazole; Neoplasms; Organometallic Compounds; Positron-Emission Tomography; Radiation-Sensitizing Agents; Thiosemicarbazones | 2011 |
Alternative PET tracers in head and neck cancer. A review.
Topics: Amino Acids; Antibodies, Monoclonal; Carbon Radioisotopes; Carcinoma, Squamous Cell; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Nitroimidazoles; Nucleosides; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Usefulness of FMISO-PET for glioma analysis.
Topics: Adult; Animals; Brain Neoplasms; Diagnosis, Differential; Fluorine Radioisotopes; Glioblastoma; Glioma; Humans; Misonidazole; Oxygen; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results | 2013 |
PET/MRI radiotracer beyond ¹⁸F-FDG.
Topics: Carbon Radioisotopes; Choline; Fluorine Radioisotopes; Humans; Levodopa; Magnetic Resonance Imaging; Misonidazole; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Sodium Fluoride | 2014 |
[Metabolic tailoring in radiotherapy for head and neck cancer].
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Clinical Trials as Topic; Diffusion Magnetic Resonance Imaging; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Misonidazole; Multimodal Imaging; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Tumor Burden | 2014 |
Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation.
Topics: Animals; Cell Hypoxia; Glioma; Humans; Misonidazole; Positron-Emission Tomography; Translational Research, Biomedical; Treatment Failure | 2015 |
F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.
Topics: Animals; Cell Hypoxia; Humans; Misonidazole; Molecular Imaging; Neoplasms; Precision Medicine; Tumor Microenvironment | 2015 |
PET-specific parameters and radiotracers in theoretical tumour modelling.
Topics: Cell Proliferation; Coordination Complexes; Dideoxynucleosides; Diffusion; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrogen-Ion Concentration; Hypoxia; Misonidazole; Models, Theoretical; Multimodal Imaging; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones; Tomography, X-Ray Computed | 2015 |
Tumor hypoxia: a new PET imaging biomarker in clinical oncology.
Topics: Biomarkers; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Tumor Hypoxia | 2016 |
[Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy].
Topics: Animals; Boron Compounds; Boron Neutron Capture Therapy; Coordination Complexes; Fluorine Radioisotopes; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Organometallic Compounds; Phenylalanine; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones | 2015 |
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.
Topics: Angiogenesis Inhibitors; Cell Hypoxia; Drug Resistance, Neoplasm; Humans; Misonidazole; Neovascularization, Pathologic; Precision Medicine; Stromal Cells; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2017 |
Hypoxia imaging and radiotherapy: bridging the resolution gap.
Topics: Cell Hypoxia; Humans; Hypoxia; Misonidazole; Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2017 |
[Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
Topics: Animals; Glutathione; Glutathione Transferase; Humans; Hypoxia; Mass Spectrometry; Mice; Misonidazole; Molecular Imaging; Molecular Probes; Multidrug Resistance-Associated Proteins; Neoplasms; Nitroimidazoles; Positron-Emission Tomography | 2018 |
Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Topics: Acetates; Carbon Radioisotopes; Dideoxynucleosides; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Lung Neoplasms; Methionine; Misonidazole; Neoplasm Staging; Neuroendocrine Tumors; Peptides; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Quinolines; Radiopharmaceuticals; Sensitivity and Specificity | 2020 |
Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Topics: Cell Hypoxia; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Multicenter Studies as Topic; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
Topics: Abdominal Pain; Animals; Biomarkers; Disease Progression; Dyspepsia; Fluorodeoxyglucose F18; Humans; Hypoxia; Idiopathic Pulmonary Fibrosis; Mice; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Prevalence; Radiopharmaceuticals; Sleep Wake Disorders | 2021 |
32 trial(s) available for fluoromisonidazole and misonidazole
| Article | Year |
|---|---|
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Middle Aged; Misonidazole; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Tirapazamine; Tomography, Emission-Computed; Triazines | 2001 |
[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Topics: Adult; Aged; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Neoplasm Staging; Radiopharmaceuticals; Soft Tissue Neoplasms; Tomography, Emission-Computed; Vascular Endothelial Growth Factor A | 2003 |
Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain; Brain Ischemia; Cell Survival; Disease Progression; Female; Fluorine Radioisotopes; Humans; Hypoxia, Brain; Infarction, Middle Cerebral Artery; Male; Middle Aged; Misonidazole; Predictive Value of Tests; Stroke; Tomography, Emission-Computed | 2003 |
pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Topics: Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Misonidazole; Oximetry; Oxygen; Oxygen Consumption; Polarography; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Topics: Adult; Aged; Blood Flow Velocity; Brain; Brain Neoplasms; Female; Humans; Hypoxia, Brain; Male; Middle Aged; Misonidazole; Oxygen Radioisotopes; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Water | 2004 |
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorine Radioisotopes; Germany; Head and Neck Neoplasms; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Misonidazole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2005 |
A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia.
Topics: Cell Hypoxia; Computer Simulation; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Kinetics; Misonidazole; Models, Biological; Neovascularization, Pathologic; Oxygen; Oxygen Consumption; Radioisotope Dilution Technique; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glioma; Glucose; Humans; Male; Metabolic Clearance Rate; Middle Aged; Misonidazole; Neovascularization, Pathologic; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Statistics as Topic | 2006 |
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Pulmonary Embolism; Radiopharmaceuticals; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Misonidazole; Neoadjuvant Therapy; Positron-Emission Tomography; Treatment Outcome | 2011 |
Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Female; Glioblastoma; Humans; Male; Methionine; Middle Aged; Misonidazole; Positron-Emission Tomography; Tumor Burden | 2011 |
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Topics: Adult; Aged; Anaplasia; Biological Transport; Brain Neoplasms; Diagnosis, Differential; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Misonidazole; Neoplasm Grading; Positron-Emission Tomography | 2012 |
Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Topics: Adult; Cell Hypoxia; Chordoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Skull Base Neoplasms; Tomography, X-Ray Computed; Young Adult | 2012 |
Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Humans; Hypoxia; Lung Neoplasms; Magnetic Resonance Imaging; Misonidazole; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
Topics: Adult; Aged; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Topics: Adult; Aged; Algorithms; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Misonidazole; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tumor Burden | 2013 |
Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
Topics: Aged; Carcinoma, Squamous Cell; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Burden | 2013 |
[18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.
Topics: Adult; Aged; Cell Hypoxia; Chordoma; Feasibility Studies; Female; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Recurrence, Local; Photons; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Proton Therapy; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Sacrococcygeal Region; Spinal Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed | 2015 |
Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Feasibility Studies; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Treatment Outcome; Tumor Burden | 2015 |
Robustness of quantitative hypoxia PET image analysis for predicting local tumor control.
Topics: Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multicenter Studies as Topic; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Squamous Cell Carcinoma of Head and Neck | 2015 |
The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Topics: Adult; Aged; Dose Fractionation, Radiation; Down-Regulation; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Tumor Hypoxia | 2016 |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
Topics: Adult; Aged; Demography; Female; Humans; Hypoxia; Lung Neoplasms; Male; Middle Aged; Misonidazole; Nitroimidazoles; Positron Emission Tomography Computed Tomography; Tissue Distribution | 2016 |
Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
Topics: Adult; Aged; Carcinoma; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Misonidazole; Oropharyngeal Neoplasms; Oxygen; Positron-Emission Tomography; Radiation Protection; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Image-Guided; Treatment Outcome; Tumor Hypoxia | 2016 |
[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Biomarkers, Tumor; Brain Neoplasms; Cerebral Blood Volume; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Radiosurgery; Tumor Hypoxia | 2017 |
Monitoring early response to chemoradiotherapy with
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Time Factors; Tissue Distribution; Treatment Outcome | 2017 |
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Topics: Aged; Brain; Brain Neoplasms; Female; Glioblastoma; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Proton Magnetic Resonance Spectroscopy; Radiopharmaceuticals; ROC Curve; Tumor Hypoxia | 2018 |
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia | 2019 |
Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging.
Topics: Brain Neoplasms; Carotid Artery, Common; Glioblastoma; Humans; Image Processing, Computer-Assisted; Misonidazole; Positron-Emission Tomography; Time Factors; Tumor Burden; Tumor Hypoxia | 2019 |
Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [
Topics: Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
249 other study(ies) available for fluoromisonidazole and misonidazole
| Article | Year |
|---|---|
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
Topics: Adult; Astrocytoma; Brain Neoplasms; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Tomography, Emission-Computed | 1992 |
Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography.
Topics: Animals; Dogs; Fluorine Radioisotopes; Misonidazole; Myocardial Ischemia; Myocardium; Tomography, Emission-Computed | 1992 |
Reduction of fluoromisonidazole, a new imaging agent for hypoxia.
Topics: Animals; Cell Line; Fluorine Radioisotopes; Humans; Misonidazole; NADH Dehydrogenase; Nitroreductases; Oxidation-Reduction; Oxygen; Tomography, Emission-Computed; Xanthine Oxidase | 1991 |
Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole.
Topics: Animals; Female; Fluorine Radioisotopes; Gases; Hypoxia; Infections; Misonidazole; Rats; Rats, Inbred Strains; Regional Blood Flow; Time Factors | 1991 |
Characteristics of the binding of labeled fluoromisonidazole in cells in vitro.
Topics: Animals; Cysteamine; Glucose; In Vitro Techniques; Misonidazole; Oxygen; Tritium | 1990 |
Fluoromisonidazole. A metabolic marker of myocyte hypoxia.
Topics: Animals; Creatine Kinase; Hypoxia; Misonidazole; Myocardium; Oxygen; Partial Pressure; Reference Values | 1990 |
In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium.
Topics: Animals; Coronary Disease; Dogs; Fluorine Radioisotopes; Heart; Misonidazole; Myocardium; Subcellular Fractions; Tomography, Emission-Computed, Single-Photon | 1990 |
No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues.
Topics: Fluorine Radioisotopes; Misonidazole; Neoplasms; Oxygen; Tomography, Emission-Computed | 1989 |
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
Topics: Animals; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1989 |
Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue.
Topics: Animals; Fluorine; Hypoxia; Metronidazole; Misonidazole; Nitroimidazoles; Radioisotopes; Radionuclide Imaging; Rats; Rats, Inbred Strains; Tissue Distribution | 1986 |
Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia.
Topics: Animals; Brain; Cerebral Infarction; Cerebrovascular Circulation; Fluorine; Gerbillinae; Hypoxia, Brain; Male; Misonidazole; Radioisotopes | 1987 |
Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.
Topics: Animals; Autoradiography; Biotransformation; Carbon Radioisotopes; Cell Line; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Hypoxia; Mice; Mice, Inbred C3H; Misonidazole; Oxygen; Radionuclide Imaging; Sarcoma, Experimental; Tritium | 1987 |
Testing of new hypoxic cell sensitizers in vivo.
Topics: Animals; Drug Evaluation, Preclinical; Etanidazole; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Radiation-Sensitizing Agents | 1982 |
Radiation response of the cells of a human malignant melanoma xenograft. Effect of hypoxic cell radiosensitizers.
Topics: Animals; Cell Survival; Dose-Response Relationship, Radiation; Humans; In Vitro Techniques; Injections, Intraperitoneal; Male; Melanoma; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Oxygen; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Transplantation, Heterologous | 1981 |
A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.
Topics: Animals; Biological Transport, Active; Biophysical Phenomena; Biophysics; Computer Simulation; Evaluation Studies as Topic; Humans; Hypoxia; Misonidazole; Models, Biological; Monte Carlo Method; Neoplasms; Radiation-Sensitizing Agents; Rats; Tomography, Emission-Computed | 1995 |
Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia.
Topics: Animals; Coronary Circulation; Deoxyglucose; Dogs; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart; Misonidazole; Myocardial Ischemia; Radionuclide Imaging; Sensitivity and Specificity; Tritium | 1995 |
Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Humans; Lung Neoplasms; Male; Middle Aged; Misonidazole; Oxygen Consumption; Radiation-Sensitizing Agents; Tomography, Emission-Computed | 1995 |
Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.
Topics: Animals; Autoradiography; Cell Hypoxia; Contrast Media; Female; Fluorine Radioisotopes; Male; Mammary Neoplasms, Experimental; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Rabbits; Rats; Rats, Inbred F344; Tissue Distribution; Tomography, Emission-Computed | 1995 |
Determination of the radiobiologically hypoxic fraction in multicellular spheroids from data on the uptake of [3H]fluoromisonidazole.
Topics: Aerobiosis; Animals; Biological Transport; Cell Hypoxia; Cell Line; Cell Survival; Cricetinae; Cricetulus; Dose-Response Relationship, Radiation; Kinetics; Microspheres; Misonidazole; Models, Theoretical; Oxygen Consumption; Radiation-Sensitizing Agents; Radioisotope Dilution Technique; Time Factors; Tritium | 1995 |
Rapid synthesis of 3-[18F]fluoro-1-(2'-nitro-1'-imidazolyl)-2-propanol ([18F]fluoromisonidazole).
Topics: Biological Assay; Fluorine Radioisotopes; Half-Life; Isotope Labeling; Magnetic Resonance Spectroscopy; Misonidazole; Pyrogens; Radiation-Sensitizing Agents; Sterilization | 1994 |
An efficient radiosynthesis of [18F]fluoromisonidazole.
Topics: Fluorine Radioisotopes; Hypoxia; Isotope Labeling; Misonidazole; Tomography, Emission-Computed | 1993 |
Application of microwave heating to the synthesis of [18F]fluoromisonidazole.
Topics: Heating; Microwaves; Misonidazole | 1993 |
Is nuclear medicine viable and can it measure viability?
Topics: Animals; Cell Hypoxia; Coronary Circulation; Dogs; Heart; Iodine Radioisotopes; Misonidazole; Myocardial Ischemia; Radionuclide Imaging | 1993 |
Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma.
Topics: Carcinoma; Case-Control Studies; Cell Hypoxia; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Misonidazole; Nasopharyngeal Neoplasms; Nasopharynx; Neck Muscles; Radiation-Sensitizing Agents; Tomography, Emission-Computed | 1996 |
Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole.
Topics: Bacteria, Anaerobic; Bacterial Infections; Carcinoma; Case-Control Studies; Cell Hypoxia; Dental Caries; Dental Pulp Diseases; Fluorine Radioisotopes; Humans; Misonidazole; Nasopharyngeal Neoplasms; Periodontal Diseases; Predictive Value of Tests; Radiation-Sensitizing Agents; Sensitivity and Specificity; Tomography, Emission-Computed | 1996 |
Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies.
Topics: Female; Fluorine Radioisotopes; Humans; Male; Misonidazole; Radiation Dosage; Radiation Protection; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed | 1997 |
Tumor hypoxia: the role of nuclear medicine.
Topics: Animals; Cell Hypoxia; Fluorine Radioisotopes; Humans; Misonidazole; Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1998 |
Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Female; Fluorine Radioisotopes; Humans; Hypoxia, Brain; Male; Misonidazole; Radiation-Sensitizing Agents; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia.
Topics: Animals; Cell Hypoxia; Female; Fluorine Radioisotopes; Hemodynamics; Hepatic Artery; Ligation; Liver; Misonidazole; Oxygen; Radiopharmaceuticals; Swine; Tomography, Emission-Computed | 1999 |
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
Topics: Animals; Autoradiography; Cell Hypoxia; Coordination Complexes; Drug Evaluation, Preclinical; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Misonidazole; Organometallic Compounds; Oxygen; Thiosemicarbazones; Tissue Distribution; Tumor Cells, Cultured | 1999 |
Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole.
Topics: Animals; Autoradiography; Cell Hypoxia; Cysteine; Female; Fluorine Radioisotopes; Iodine Radioisotopes; Mammary Neoplasms, Experimental; Metronidazole; Microelectrodes; Misonidazole; Neovascularization, Pathologic; Organotechnetium Compounds; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging; Rats; Rats, Inbred F344; Tissue Distribution | 1999 |
Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.
Topics: Animals; Carbon Radioisotopes; Deoxyglucose; Fluorine Radioisotopes; Liver Neoplasms, Experimental; Male; Methionine; Misonidazole; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Rats; Tissue Distribution | 1999 |
Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Cell Hypoxia; Chromatography, High Pressure Liquid; Contrast Media; Cricetinae; Cricetulus; Etanidazole; Female; Fibroblasts; Fibrosarcoma; Fluorine Radioisotopes; Glioma; Lung; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Rats; Sarcoma, Experimental; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 1999 |
No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage.
Topics: Aged; Aged, 80 and over; Cerebral Hemorrhage; Female; Fluorine Radioisotopes; Humans; Hypoxia, Brain; Male; Misonidazole; Radiation-Sensitizing Agents; Sensitivity and Specificity; Stroke; Tomography, Emission-Computed | 1999 |
Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.
Topics: Administration, Inhalation; Animals; Cell Hypoxia; Cell Survival; Dose-Response Relationship, Radiation; Glioma; Male; Misonidazole; Models, Biological; Oxygen; Oxygen Consumption; Predictive Value of Tests; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rats, Inbred F344; Tomography, Emission-Computed | 2000 |
The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain; Disease Progression; Female; Humans; Hypoxia-Ischemia, Brain; Male; Misonidazole; Stroke; Time Factors; Tomography, Emission-Computed | 2000 |
Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver.
Topics: Animals; Blood Gas Analysis; Electrodes; Female; Fluorine Radioisotopes; Hemodynamics; Liver; Microspheres; Misonidazole; Oxygen; Oxygen Consumption; Radiopharmaceuticals; Swine; Tomography, Emission-Computed | 2000 |
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO).
Topics: Animals; Brain Neoplasms; Cell Hypoxia; Fluorine Radioisotopes; Glioma; Intestinal Mucosa; Kidney; Liver; Male; Misonidazole; Rats; Rats, Wistar; Tissue Distribution; Tomography, Emission-Computed | 2002 |
Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following acute ischemic stroke.
Topics: Acute Disease; Aged; Brain; Brain Ischemia; Female; Fluorine Radioisotopes; Humans; Hypoxia; Male; Middle Aged; Misonidazole; Reference Values; Statistics as Topic; Stroke; Tomography, Emission-Computed | 2002 |
Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent.
Topics: Animals; Biotransformation; Chemical Phenomena; Chemistry, Physical; CHO Cells; Cricetinae; Electrons; Fluorine Radioisotopes; Hypoxia, Brain; Lipids; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution | 2002 |
Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing.
Topics: Animals; Autoradiography; Carbon Dioxide; Cell Hypoxia; Electrodes; Female; Fluorine Radioisotopes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Oxygen; Tomography, Emission-Computed | 2002 |
On biologically conformal boost dose optimization.
Topics: Algorithms; Imaging, Three-Dimensional; Misonidazole; Quality Control; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, Emission-Computed; Tongue Neoplasms | 2003 |
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.
Topics: Animals; Carcinoma 256, Walker; Female; Misonidazole; Radiation-Sensitizing Agents; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured | 2003 |
Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours.
Topics: Adult; Aged; Cell Hypoxia; Electrodes; Feasibility Studies; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Misonidazole; Oxygen; Polarography; Soft Tissue Neoplasms; Tomography, Emission-Computed | 2003 |
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Female; Fibrosarcoma; Mammary Neoplasms, Animal; Metabolic Clearance Rate; Mice; Mice, Inbred C3H; Misonidazole; Monosaccharides; Nitroimidazoles; Organ Specificity; Tissue Distribution; Tomography, Emission-Computed | 2004 |
Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
Topics: Animals; Cell Hypoxia; Female; Fluorine Radioisotopes; Mammary Neoplasms, Experimental; Metabolic Clearance Rate; Mice; Misonidazole; Nitroimidazoles; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2004 |
Imaging the ischemic penumbra with 18F-fluoromisonidazole in a rat model of ischemic stroke.
Topics: Animals; Autoradiography; Brain Ischemia; Infarction, Middle Cerebral Artery; Male; Misonidazole; Rats; Rats, Sprague-Dawley; Stroke; Tomography, Emission-Computed | 2004 |
Penumbral topography in human stroke: methodology and validation of the 'Penumbragram'.
Topics: Aged; Aged, 80 and over; Algorithms; Brain; Brain Ischemia; Brain Mapping; Factor Analysis, Statistical; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Misonidazole; Prognosis; Reference Values; Sensitivity and Specificity; Statistics as Topic; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Hypoxia-Ischemia, Brain; Male; Middle Aged; Misonidazole; Prognosis; Recovery of Function; Severity of Illness Index; Time Factors; Tomography, Emission-Computed | 2004 |
A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia.
Topics: Adenocarcinoma; Animals; Arabinofuranosyluracil; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; DNA-Binding Proteins; Drug Evaluation, Preclinical; Feasibility Studies; Fluorine Radioisotopes; Gene Expression Profiling; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Iodine Radioisotopes; Misonidazole; Nuclear Proteins; Radionuclide Imaging; Radiopharmaceuticals; Rats; Thymidine Kinase; Transcription Factors; Viral Proteins | 2004 |
Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.
Topics: Animals; Antibodies, Monoclonal; Carbonic Anhydrase III; Cell Hypoxia; Fluorodeoxyglucose F18; Heart; Immunoenzyme Techniques; Lung; Male; Misonidazole; Muscles; Nitroimidazoles; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rhabdomyosarcoma | 2004 |
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Topics: Animals; Cell Hypoxia; Disease Models, Animal; Female; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Organ Specificity; Oxidation-Reduction; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2005 |
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
Topics: Animals; Autoradiography; Benzimidazoles; Cell Hypoxia; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Microscopy, Fluorescence; Misonidazole; Neoplasms; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rats, Nude; Thiosemicarbazones; Transplantation, Heterologous | 2005 |
Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Oxygen Consumption; Partial Pressure; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals | 2005 |
Fully automated one-pot synthesis of [18F]fluoromisonidazole.
Topics: Chromatography, High Pressure Liquid; Fluorine Radioisotopes; Misonidazole | 2005 |
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Hypoxia; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Nephrectomy; Oxygen; Polarography; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module.
Topics: Drug Evaluation, Preclinical; Drug Stability; Equipment Design; Equipment Failure Analysis; Fluorodeoxyglucose F18; Misonidazole; Radiopharmaceuticals; Robotics; Staining and Labeling | 2005 |
NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
Topics: Animals; Cell Hypoxia; Equipment Design; Equipment Failure Analysis; Feasibility Studies; Female; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Nanotechnology; Neoplasms, Experimental; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution | 2006 |
Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Kinetics; Male; Middle Aged; Misonidazole; Models, Statistical; Positron-Emission Tomography; Radiation-Sensitizing Agents; Software; Treatment Outcome | 2005 |
Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.
Topics: Animals; Carcinoma, Squamous Cell; Equipment Design; Equipment Failure Analysis; Fluorodeoxyglucose F18; Humans; Male; Misonidazole; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Reproducibility of Results; Restraint, Physical; Sensitivity and Specificity; Species Specificity; Subtraction Technique | 2006 |
Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.
Topics: Animals; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Glucose Transporter Type 1; Humans; Immunohistochemistry; Mammary Neoplasms, Animal; Mice; Misonidazole; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Positron-Emission Tomography; Pyridines; Transplantation, Homologous | 2006 |
Characterization of fluoromisonidazole binding in stroke.
Topics: Animals; Autoradiography; Brain; Cell Hypoxia; Cerebrovascular Circulation; Contrast Media; Fluorine Radioisotopes; Hypoxia, Brain; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Misonidazole; Positron-Emission Tomography; Protein Binding; Radioactive Tracers; Rats; Rats, Sprague-Dawley; Reperfusion; Time Factors | 2006 |
FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hypoxia; Misonidazole; Neoplasm Metastasis; Oxygen; Polarography; Positron-Emission Tomography; Reference Standards | 2006 |
Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging | 2006 |
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Topics: Aged; Cell Hypoxia; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2006 |
Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Misonidazole; Multivariate Analysis; Positron-Emission Tomography; Survival Analysis | 2006 |
Imaging of brain hypoxia in permanent and temporary middle cerebral artery occlusion in the rat using 18F-fluoromisonidazole and positron emission tomography: a pilot study.
Topics: Anesthesia; Animals; Hypoxia, Brain; Image Interpretation, Computer-Assisted; Infarction, Middle Cerebral Artery; Kinetics; Ligation; Male; Middle Cerebral Artery; Misonidazole; Models, Biological; Necrosis; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred SHR; Stroke | 2007 |
A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data.
Topics: Cell Hypoxia; Computer Simulation; Humans; Image Interpretation, Computer-Assisted; Misonidazole; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
From anatomical to biological target volumes: the role of PET in radiation treatment planning.
Topics: Cell Hypoxia; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Misonidazole; Neoplasms; Observer Variation; Patient Care Planning; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2006 |
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Misonidazole; Neovascularization, Pathologic; Radionuclide Imaging; Radiopharmaceuticals; Statistics as Topic | 2006 |
The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Coordination Complexes; Mice; Misonidazole; Neoplasm Transplantation; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Thiosemicarbazones | 2007 |
A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO).
Topics: Fluorine Radioisotopes; Hypoxia; Misonidazole; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Robotics | 2007 |
A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations.
Topics: Algorithms; Cell Hypoxia; Head and Neck Neoplasms; Humans; Misonidazole; Models, Biological; Oxygen; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Burden | 2007 |
Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells.
Topics: Cell Hypoxia; Cell Line; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Misonidazole; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Vascular Endothelial Growth Factor A | 2007 |
Hypoxia dose painting by numbers: a planning study.
Topics: Cell Hypoxia; Feasibility Studies; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2007 |
pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle o
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Misonidazole; Oxygen Consumption; Polarography; Positron-Emission Tomography; Prognosis; Ultrasonography, Doppler, Color | 2007 |
Altered calcium homeostasis in motor neurons following AMPA receptor but not voltage-dependent calcium channels' activation in a genetic model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Calcium; Calcium Channels; Cells, Cultured; Disease Models, Animal; Homeostasis; Humans; Immunohistochemistry; Mice; Mice, Transgenic; Misonidazole; Motor Neurons; Patch-Clamp Techniques; Receptors, AMPA; Superoxide Dismutase | 2007 |
Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.
Topics: Animals; Disease Models, Animal; Half-Life; Hypoxia; Liver Neoplasms, Experimental; Misonidazole; Monosaccharides; Nitroimidazoles; Peritoneal Neoplasms; Positron-Emission Tomography; Rats; Tissue Distribution | 2008 |
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Topics: Cell Hypoxia; Feasibility Studies; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Radiation-Sensitizing Agents; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2008 |
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Topics: Aged; Cell Hypoxia; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2008 |
The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
Topics: Cell Hypoxia; Feasibility Studies; Follow-Up Studies; Head and Neck Neoplasms; Humans; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2008 |
Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Topics: Animals; Autoradiography; Biomarkers, Tumor; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Misonidazole; Nitroimidazoles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Regression Analysis | 2008 |
Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
Topics: Animals; Fluorine Radioisotopes; Hypoxia; Male; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Radiopharmaceuticals; Tissue Distribution | 2008 |
Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Topics: Antimetabolites, Antineoplastic; Cell Hypoxia; Combined Modality Therapy; Dideoxynucleosides; Fluorodeoxyglucose F18; Fluorouracil; Humans; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2008 |
Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Topics: Animals; Autoradiography; Cell Line, Tumor; Coordination Complexes; Copper Radioisotopes; Dideoxynucleosides; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gliosarcoma; Humans; Metabolic Clearance Rate; Misonidazole; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred F344; Thiosemicarbazones; Tissue Distribution | 2008 |
[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
Topics: Animals; Autoradiography; Biomarkers; Heart; Hypoxia; Male; Misonidazole; Myocardium; Nitroimidazoles; Positron-Emission Tomography; Rats; Reference Values; Rhabdomyosarcoma; Tissue Distribution | 2009 |
Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
Topics: Animals; Antigens, Neoplasm; Arabinofuranosyluracil; Autoradiography; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Etanidazole; Female; Gene Expression; Green Fluorescent Proteins; Herpesvirus 1, Human; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Immunohistochemistry; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Neoplasms; Nitroimidazoles; Positron-Emission Tomography; Thymidine Kinase; Tissue Distribution; Transplantation, Heterologous | 2008 |
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Topics: Adult; Aged; Female; Gadolinium; Glioblastoma; Humans; Hypoxia; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Survival Analysis; Tumor Burden | 2009 |
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Laryngeal Neoplasms; Middle Aged; Misonidazole; Oropharyngeal Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tumor Burden | 2009 |
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
Topics: Animals; Autoradiography; Cell Hypoxia; Disease Models, Animal; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Rats | 2009 |
Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model.
Topics: Animals; Autoradiography; Cell Line, Tumor; Diagnosis, Differential; Disease Models, Animal; Fluoroacetates; Fluorodeoxyglucose F18; Inflammation; Male; Mice; Misonidazole; Positron-Emission Tomography; Radioactive Tracers; Sarcoma; Tissue Distribution | 2009 |
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
Topics: Adult; Brain Neoplasms; Cell Division; Computer Simulation; Contrast Media; Female; Fluorine Radioisotopes; Gadolinium; Glioblastoma; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Neoplasm Invasiveness; Positron-Emission Tomography | 2009 |
Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging.
Topics: Algorithms; Computer Simulation; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Misonidazole; Models, Biological; Neoplasms; Oxygen; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Characterisation of the timing of binding of the hypoxia tracer FMISO after stroke.
Topics: Animals; Autoradiography; Brain; Cerebrovascular Circulation; Hypoxia-Ischemia, Brain; Image Interpretation, Computer-Assisted; Infarction, Middle Cerebral Artery; Misonidazole; Radiation-Sensitizing Agents; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Time Factors | 2009 |
Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Mice; Misonidazole; Models, Biological; Neoplasm Transplantation; Positron-Emission Tomography; Response Elements; Time Factors; Transcription, Genetic | 2009 |
Imaging of hypoxic-ischemic penumbra with (18)F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage.
Topics: Aged; Brain Chemistry; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Circulation; Female; Glasgow Outcome Scale; Glucose; Glutamic Acid; Humans; Hypoxia, Brain; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Nervous System Diseases; Perfusion; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Subarachnoid Hemorrhage; Tomography, X-Ray Computed; Vasospasm, Intracranial | 2010 |
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric | 2010 |
Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET.
Topics: Acute Disease; Algorithms; Cell Hypoxia; Chronic Disease; Computer Simulation; Head and Neck Neoplasms; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Misonidazole; Models, Biological; Oxygen; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique | 2009 |
A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements.
Topics: Algorithms; Animals; Cell Hypoxia; Cell Line, Tumor; Fiber Optic Technology; Imaging, Three-Dimensional; Immunohistochemistry; Misonidazole; Neoplasms, Experimental; Oxygen; Positron-Emission Tomography; Rats; Rats, Nude; Robotics | 2009 |
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.
Topics: Aged; Female; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Neoplasm Staging; Plasma; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow | 2010 |
Simulation of tissue activity curves of (64)Cu-ATSM for sub-target volume delineation in radiotherapy.
Topics: Algorithms; Blood Vessels; Cell Hypoxia; Computer Simulation; Contrast Media; Coordination Complexes; Copper Radioisotopes; Diffusion; Humans; Misonidazole; Models, Biological; Neoplasms; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Thiosemicarbazones | 2010 |
The possibility of a fully automated procedure for radiosynthesis of fluorine-18-labeled fluoromisonidazole using a simplified single, neutral alumina column purification procedure.
Topics: Aluminum Oxide; Animals; Automation; Chromatography; Fibrosarcoma; Fluorine Radioisotopes; Humans; Misonidazole; Positron-Emission Tomography; Rabbits; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tissue Distribution | 2010 |
Evaluation of hypoxic tissue dynamics with 18F-FMISO PET in a rat model of permanent cerebral ischemia.
Topics: Animals; Brain Ischemia; Cell Hypoxia; Disease Models, Animal; Male; Misonidazole; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Staining and Labeling; Time Factors | 2011 |
Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET.
Topics: Animals; Biomarkers; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Neoplastic; Chemical Phenomena; Drug Evaluation, Preclinical; Female; Glutathione; Kinetics; Mice; Misonidazole; Models, Biological; Neoplasms; Oxidation-Reduction; Positron-Emission Tomography; Propanols; Radioactive Tracers; Triazoles; Xanthine Oxidase | 2010 |
Parametric mapping of [18F]fluoromisonidazole positron emission tomography using basis functions.
Topics: Algorithms; Animals; Brain Ischemia; Brain Mapping; Computer Simulation; Data Interpretation, Statistical; Infarction, Middle Cerebral Artery; Kinetics; Least-Squares Analysis; Misonidazole; Models, Statistical; Nonlinear Dynamics; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Stroke | 2011 |
Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode.
Topics: Biosensing Techniques; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Hypoxia; Microchemistry; Microelectrodes; Misonidazole; Neoplasms; Oxygen; Positron-Emission Tomography; Sarcoma; Soft Tissue Neoplasms | 2010 |
'Salvaged' stroke ischaemic penumbra shows significant injury: studies with the hypoxia tracer FMISO.
Topics: Animals; Autoradiography; Brain; Brain Ischemia; Cerebral Infarction; Hypoxia; Misonidazole; Rats; Rats, Sprague-Dawley; Stroke; Time Factors; Tissue Distribution | 2011 |
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients wit
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
Topics: Carcinoma, Small Cell; Female; Head and Neck Neoplasms; Humans; Image Enhancement; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Time Factors | 2011 |
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; HT29 Cells; Humans; Mice; Mice, Nude; Misonidazole; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xanthones | 2011 |
Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps.
Topics: Diffusion; Finite Element Analysis; Hypoxia; Microvessels; Misonidazole; Models, Biological; Oxygen; Positron-Emission Tomography; Staining and Labeling | 2011 |
Multiagent PET for risk characterization in sarcoma.
Topics: Carbon Dioxide; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Isotope Labeling; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Risk Assessment; Sarcoma; Thymidine; Verapamil | 2011 |
Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.
Topics: Adult; Brain Neoplasms; Cell Proliferation; Computer Simulation; Fluorine Radioisotopes; Glioblastoma; Glioma; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Mathematical Concepts; Misonidazole; Models, Biological; Necrosis; Neoplasm Invasiveness; Neovascularization, Pathologic; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; User-Computer Interface | 2012 |
Anti-VEGF antibody treatment accelerates polycystic kidney disease.
Topics: Animals; Antibodies, Neutralizing; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Misonidazole; Organ Size; Polycystic Kidney Diseases; Proteinuria; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Severity of Illness Index; Vascular Endothelial Growth Factor A | 2011 |
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.
Topics: Biological Transport; Cell Hypoxia; Coordination Complexes; Copper Radioisotopes; Electrochemistry; Head and Neck Neoplasms; Humans; Misonidazole; Models, Biological; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radioactive Tracers; Reproducibility of Results; Thiosemicarbazones; Time Factors | 2011 |
Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Topics: Angiogenesis Inhibitors; Animals; Biological Transport; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cerebrovascular Circulation; Disease Models, Animal; Glioma; Indoles; Kinetics; Magnetic Resonance Imaging; Misonidazole; Neovascularization, Pathologic; Permeability; Positron-Emission Tomography; Pyrroles; Rats; Sunitinib; Treatment Outcome | 2011 |
Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
Topics: Cell Hypoxia; Head and Neck Neoplasms; Humans; Misonidazole; Positron-Emission Tomography; Radiation Tolerance; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated | 2011 |
Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma.
Topics: Fluorodeoxyglucose F18; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography | 2011 |
Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
Topics: Adenocarcinoma; Anesthesia; Animals; Coordination Complexes; Copper Radioisotopes; Female; Fluorine Radioisotopes; Gases; Hypoxia; Mice; Mice, Inbred CBA; Misonidazole; Muscles; Neoplasms, Experimental; Organometallic Compounds; Organotechnetium Compounds; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Thiosemicarbazones; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2011 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2012 |
Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging.
Topics: Acute Disease; Chronic Disease; Computer Simulation; Fluorine Radioisotopes; Humans; Hypoxia; Misonidazole; Models, Biological; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; Child, Preschool; Female; Glioma; Humans; Hypoxia; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiation-Sensitizing Agents; Retrospective Studies; Young Adult | 2012 |
[18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Case-Control Studies; Cell Hypoxia; Female; Humans; Laryngeal Neoplasms; Lutetium; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Multimodal Imaging; Nasopharyngeal Neoplasms; Nasopharynx; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Semiconductors; Silicates; Thyroid Neoplasms; Tomography, X-Ray Computed | 2013 |
Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.
Topics: Animals; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Misonidazole; Models, Biological; Molecular Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Reproducibility of Results | 2013 |
Design, synthesis, and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors.
Topics: Cell Hypoxia; Cell Line, Tumor; Drug Design; Glucose Transport Proteins, Facilitative; Glucosides; Glycosides; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Transcriptional Activation | 2012 |
Polymeric nanoparticles of FMISO: are nano-radiopharmaceuticals better than conventional ones?
Topics: Microscopy, Atomic Force; Misonidazole; Nanoparticles; Radiation-Sensitizing Agents; Radiopharmaceuticals | 2012 |
¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Hypoxia; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Multimodal Imaging; Nitroimidazoles; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles | 2012 |
Dose-response relationships of FMISO between trace dose and various macro-doses in rat by ultra-performance liquid chromatography with mass spectrometry and radioactivity analysis.
Topics: Animals; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Stability; Half-Life; Injections, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Microfluidic single vessel production of hypoxia tracer 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole ([18F]-FMISO).
Topics: Fluorine Radioisotopes; Microfluidics; Misonidazole; Oxygen | 2012 |
Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats.
Topics: Animals; Cell Hypoxia; Kinetics; Male; Misonidazole; Models, Biological; Oxygen; Positron-Emission Tomography; Pressure; Rats; Skin Neoplasms | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
Topics: Aged; Cell Hypoxia; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies | 2012 |
PET/CT in the management and prognosis of pancreatic exocrine tumors.
Topics: Female; Humans; Male; Misonidazole; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Cohort Studies; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Models, Biological; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2013 |
High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Topics: Adult; Aged; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypoxia; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Nuclear Medicine; Positron-Emission Tomography; Prognosis; Radiation Oncology; Radiopharmaceuticals; Reproducibility of Results; Time Factors | 2013 |
Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.
Topics: Animals; Autoradiography; Biological Transport; Brain Neoplasms; Cell Hypoxia; Cell Proliferation; Fluorodeoxyglucose F18; Glioma; Glucose; Glucose Transporter Type 1; Hexokinase; Hypoxia-Inducible Factor 1; Ki-67 Antigen; Male; Misonidazole; Nitroimidazoles; Rats; Rats, Wistar; Tissue Distribution | 2013 |
Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma.
Topics: Glioma; Humans; Hypoxia; Immunohistochemistry; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Misonidazole; Positron-Emission Tomography | 2013 |
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Ki-67 Antigen; Letrozole; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasms, Hormone-Dependent; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles | 2013 |
18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Female; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2013 |
Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fluorides; Fluorodeoxyglucose F18; Humans; Mice; Misonidazole; Osteoblasts; Osteoclasts; Osteosarcoma; Phenotype; Positron-Emission Tomography; Tibia | 2013 |
Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.
Topics: Cell Hypoxia; Chemoradiotherapy; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Male; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.
Topics: Animals; Carcinoma, Squamous Cell; Computer Simulation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Mice; Microvessels; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tumor Cells, Cultured | 2013 |
Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Tumor Suppressor Protein p53 | 2014 |
Diffusion and perfusion correlates of the 18F-MISO PET lesion in acute stroke: pilot study.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Female; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Stroke | 2014 |
Event-by-event respiratory motion correction for PET with 3D internal-1D external motion correlation.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Healthy Volunteers; Humans; Hypoxia; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Insulin-Secreting Cells; Kidney; Lung Neoplasms; Misonidazole; Movement; Pancreas; Positron-Emission Tomography; Regression Analysis; Reproducibility of Results; Respiration; Signal Processing, Computer-Assisted; Tetrabenazine; X-Ray Microtomography | 2013 |
Development of a new precursor-minimizing base control method and its application for the automated synthesis and SPE purification of [(18) F]fluoromisonidazole ([(18) F]FMISO).
Topics: Isotope Labeling; Misonidazole; Radiopharmaceuticals; Solid Phase Extraction | 2013 |
Preclinical evaluation of parametric image reconstruction of [18F]FMISO PET: correlation with ex vivo immunohistochemistry.
Topics: Animals; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice; Misonidazole; Positron-Emission Tomography | 2014 |
Nitrite induces the extravasation of iron oxide nanoparticles in hypoxic tumor tissue.
Topics: Animals; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Ferric Compounds; Misonidazole; Nanoparticles; Nitrites; Positron-Emission Tomography; Rats; Rats, Wistar; Time Factors | 2014 |
Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using ¹⁸F-fluoromisonidazole positron emission tomographic imaging.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Disease Models, Animal; Disease Progression; Fluorine Radioisotopes; Hypoxia; Male; Misonidazole; Positron-Emission Tomography; Rabbits; Radiation-Sensitizing Agents; Reproducibility of Results; Severity of Illness Index | 2014 |
Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Radiation; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Random Allocation; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2014 |
Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Positron-Emission Tomography; Preoperative Period; Treatment Outcome | 2014 |
Dual acquisition of (18)F-FMISO and (18)F-FDOPA.
Topics: Dihydroxyphenylalanine; Humans; Image Processing, Computer-Assisted; Kinetics; Misonidazole; Models, Biological; Positron-Emission Tomography; Radiation Dosage | 2014 |
Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Head and Neck Neoplasms; Heterografts; Humans; Hypoxia; Male; Mice; Misonidazole; Radionuclide Imaging; Radiopharmaceuticals; Tumor Burden | 2014 |
Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
Topics: Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Humans; Male; Middle Aged; Misonidazole; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Tumor Burden | 2015 |
A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Computer Simulation; Imidazoles; Misonidazole; Models, Biological; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Reproducibility of Results; Rhabdomyosarcoma; Sensitivity and Specificity; Triazoles | 2015 |
A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.
Topics: Aged; Brain Neoplasms; Glioma; Humans; Hypoxia; Male; Misonidazole; Models, Biological; Positron-Emission Tomography; Precision Medicine; Radiation-Sensitizing Agents; Radiography | 2015 |
A (99m)Tc-labeled misonidazole analogue: step toward a (99m)Tc-alternative to [18F]fluromisonidazole for detecting tumor hypoxia.
Topics: Animals; Fibrosarcoma; Hypoxia; Mice; Misonidazole; Organotechnetium Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2015 |
Automated synthesis and PET evaluation of both enantiomers of [¹⁸F]FMISO.
Topics: Animals; Automation; Cell Line, Tumor; Chemistry Techniques, Synthetic; Female; Humans; Mice; Misonidazole; Positron-Emission Tomography; Radiochemistry; Stereoisomerism; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Misonidazole; Molecular Targeted Therapy; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2016 |
Synthesis of [(18)F]FMISO in a flow-through microfluidic reactor: Development and clinical application.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Fluorine Radioisotopes; Humans; Hypoxia; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Microfluidics; Misonidazole; Pilot Projects; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiochemistry; Tissue Distribution | 2015 |
Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Mice, Nude; Misonidazole; Multimodal Imaging; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Coloring Agents; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Heterografts; Mice; Mice, Nude; Misonidazole; Neoplasm Recurrence, Local; Nitroimidazoles; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
Topics: Adult; Aged; Aged, 80 and over; Aorta; Brain Neoplasms; Cerebellum; Disease Progression; Female; Heart; Humans; Hypoxia; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neoplasms; Oxygen; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Tissue Distribution; Treatment Outcome | 2015 |
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib | 2015 |
Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
Topics: Humans; Hypoxia; Imidazoles; Misonidazole; Models, Theoretical; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Triazoles | 2015 |
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Topics: Aged; Aged, 80 and over; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Misonidazole; Pilot Projects; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
18F-Misonidazole PET-CT scan detection of occult bone metastasis.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Humans; Lung Neoplasms; Male; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
(18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer.
Topics: Animals; Autoradiography; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; Heterografts; Humans; Hypoxia; Image Processing, Computer-Assisted; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Nude; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Evaluation of Tumor-associated Stroma and Its Relationship with Tumor Hypoxia Using Dynamic Contrast-enhanced CT and (18)F Misonidazole PET in Murine Tumor Models.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Glioblastoma; Hypoxia; Immunohistochemistry; Mice; Misonidazole; Pancreatic Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiographic Image Interpretation, Computer-Assisted; Tomography, X-Ray Computed | 2016 |
The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.
Topics: Animals; Diagnostic Imaging; Hypoxia; Male; Mass Spectrometry; Metabolome; Metabolomics; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Molecular Probes; Molecular Weight; Neoplasms; Radionuclide Imaging; Reproducibility of Results; Tandem Mass Spectrometry; Tissue Distribution | 2015 |
Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.
Topics: Algorithms; Animals; Carcinoma, Squamous Cell; Cohort Studies; Colorectal Neoplasms; Head and Neck Neoplasms; HT29 Cells; Humans; Hypoxia; Image Processing, Computer-Assisted; Misonidazole; Neoplasm Transplantation; Perfusion; Radionuclide Imaging; Radiopharmaceuticals; Rats; Reproducibility of Results; Retrospective Studies; ROC Curve | 2016 |
Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.
Topics: Animals; Choline; Male; Mice; Mice, Nude; Misonidazole; Monitoring, Physiologic; Multimodal Imaging; Positron-Emission Tomography; Radiotherapy; Tomography, X-Ray Computed | 2015 |
Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice, Nude; Misonidazole; Positron-Emission Tomography; Reproducibility of Results; Xenograft Model Antitumor Assays | 2016 |
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones | 2016 |
(18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cerebellum; Female; Humans; Male; Middle Aged; Misonidazole; Necrosis; Positron-Emission Tomography | 2016 |
Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging.
Topics: Adult; Aged; Coronary Circulation; Exercise Test; Female; Heart Diseases; Humans; Image Processing, Computer-Assisted; Insulin-Secreting Cells; Male; Misonidazole; Models, Statistical; Motion; Positron-Emission Tomography; Radiopharmaceuticals; Respiratory Mechanics; Rest; Rubidium Radioisotopes; Young Adult | 2016 |
Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Topics: Animals; Benzoquinones; Cell Line, Tumor; Down-Regulation; Fluorodeoxyglucose F18; Glioma; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Misonidazole; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tumor Hypoxia | 2016 |
Pathophysiologic Mechanisms of Cerebral Ischemia and Diffusion Hypoxia in Traumatic Brain Injury.
Topics: Adult; Aged; Brain Injuries, Traumatic; Brain Ischemia; Case-Control Studies; Cerebrovascular Circulation; Female; Humans; Hypoxia; Male; Middle Aged; Misonidazole; Oximetry; Oxygen; Positron-Emission Tomography | 2016 |
Topics: Aged; Cardiomyopathies; Diagnosis, Differential; Female; Humans; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis; Whole Body Imaging | 2017 |
Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Tumor Burden; Uterine Cervical Neoplasms | 2016 |
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tumor Hypoxia | 2016 |
Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: A question of O2 consumption?
Topics: Animals; Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Computer Simulation; Feasibility Studies; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Hypoxia; Mice, Nude; Misonidazole; Models, Biological; Neoplasm Transplantation; Nitroimidazoles; Oxygen Consumption; Platelet Endothelial Cell Adhesion Molecule-1; Tumor Microenvironment | 2016 |
Quantitative [
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Female; Fluorescent Antibody Technique; Mammary Neoplasms, Animal; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Tumor Hypoxia | 2017 |
Molecular Imaging of Tumor Hypoxia: Existing Problems and Their Potential Model-Based Solutions.
Topics: Biomarkers, Tumor; Computer Simulation; Contrast Media; Diffusion; Humans; Microcirculation; Misonidazole; Models, Biological; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Oxygen; Phantoms, Imaging; Signal-To-Noise Ratio; Tumor Hypoxia; Tumor Microenvironment | 2016 |
Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Cell Tracking; Heterografts; Humans; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Positron-Emission Tomography | 2016 |
Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO).
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chromatography, High Pressure Liquid; Glioblastoma; Humans; Mice; Misonidazole; Positron Emission Tomography Computed Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Tissue Distribution | 2016 |
Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Immunohistochemistry; Ku Autoantigen; Male; Middle Aged; Misonidazole; Papillomavirus Infections; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Hypoxia | 2016 |
Hypoxia Radiotracer Produced Automatically in Dose-on-Demand Fashion.
Topics: Animals; Automation; Chemistry Techniques, Synthetic; Drug Industry; Humans; Hypoxia; Mice; Misonidazole; Positron-Emission Tomography; Quality Control; Radiopharmaceuticals | 2016 |
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Topics: Adult; Aged; Blood Glucose; Brain Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glioblastoma; Glycolysis; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Oxygen; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
The role of necrosis, acute hypoxia and chronic hypoxia in
Topics: Computer Simulation; Humans; Hypoxia; Misonidazole; Models, Theoretical; Necrosis; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Spheroids, Cellular | 2016 |
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Glioma; Humans; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2016 |
Matching the reaction-diffusion simulation to dynamic [
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Diffusion; Female; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, Nude; Misonidazole; Models, Biological; Neoplasms, Squamous Cell; Oxygen; Positron-Emission Tomography; Tumor Hypoxia; Tumor Microenvironment | 2017 |
Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Topics: Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neovascularization, Pathologic; Observer Variation; Oxygen; Perfusion Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tumor Hypoxia | 2017 |
Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Topics: Contrast Media; Head and Neck Neoplasms; Humans; Kinetics; Magnetic Resonance Imaging; Misonidazole; Positron-Emission Tomography | 2017 |
Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Humans; Kinetics; Male; Mice, Inbred BALB C; Misonidazole; Muscles; Neoplasms; Oxygen; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Brain hypoxia mapping in acute stroke: Back-to-back T2' MR versus
Topics: Acute Disease; Animals; Hypoxia, Brain; Magnetic Resonance Imaging; Male; Misonidazole; Positron Emission Tomography Computed Tomography; Rats; Rats, Wistar; Reproducibility of Results; Rodentia; Stroke | 2017 |
Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography.
Topics: Brain Neoplasms; Cerebellum; Female; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Sensitivity and Specificity; Tumor Hypoxia | 2018 |
Players of 'hypoxia orchestra' - what is the role of FMISO?
Topics: Humans; Misonidazole; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Hypoxia | 2017 |
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Humans; Kinetics; Lung Neoplasms; Misonidazole; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals | 2017 |
FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state.
Topics: Cell Line, Tumor; Glutathione; Humans; Metabolic Clearance Rate; Misonidazole; Neoplasms, Experimental; Oxygen; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Tissue Distribution; Tumor Hypoxia | 2017 |
Topics: Adult; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Tumor Hypoxia | 2017 |
Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
Topics: Aged; Brain Neoplasms; Cell Hypoxia; Female; Glioma; Humans; Image Enhancement; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Positron-Emission Tomography | 2017 |
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2017 |
FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas.
Topics: Adult; Aged; Brain Mapping; Brain Neoplasms; Female; Glioblastoma; Gray Matter; Humans; Hypoxia, Brain; Male; Middle Aged; Misonidazole; Perfusion Imaging; Positron Emission Tomography Computed Tomography; Prospective Studies; ROC Curve; White Matter | 2017 |
Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.
Topics: Adult; Aged; Carcinoma; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Misonidazole; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated | 2017 |
Topics: Adult; Carcinoma; Feasibility Studies; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organs at Risk; Positron Emission Tomography Computed Tomography; Radiation Injuries; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Sampling Studies; Treatment Outcome; Tumor Burden | 2017 |
Hypoxic volume evaluated by
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Neck Dissection; Neoplasm Grading; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Tumor Hypoxia | 2018 |
Effects of hyperoxia on 18F-fluoro-misonidazole brain uptake and tissue oxygen tension following middle cerebral artery occlusion in rodents: Pilot studies.
Topics: Animals; Brain; Hyperoxia; Kinetics; Magnetic Resonance Imaging; Middle Cerebral Artery; Misonidazole; Oxygen; Pilot Projects; Positron-Emission Tomography; Rats; Rats, Wistar | 2017 |
Rapid and simplified synthesis of [
Topics: Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Fluorine Radioisotopes; Humans; Male; Misonidazole; Positron Emission Tomography Computed Tomography; Rats, Wistar; Solid Phase Extraction; Subarachnoid Hemorrhage | 2018 |
Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Misonidazole; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tumor Hypoxia | 2018 |
Modeling of FMISO [F
Topics: Blood Flow Velocity; Capillaries; Cell Hypoxia; Computer Simulation; Humans; Microcirculation; Misonidazole; Models, Cardiovascular; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Numerical Analysis, Computer-Assisted; Oxygen; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Regional Blood Flow; Tumor Microenvironment | 2018 |
Tumor Hypoxia Detected by
Topics: Adult; Aged; Disease-Free Survival; Dose Fractionation, Radiation; Humans; Middle Aged; Misonidazole; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; ROC Curve; Time Factors; Treatment Outcome; Tumor Hypoxia | 2018 |
To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoxia; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Misonidazole; Progression-Free Survival; Proportional Hazards Models; Treatment Outcome | 2018 |
Dosimetry study of
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Humans; Hypoxia; Lung Neoplasms; Male; Middle Aged; Misonidazole; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2018 |
The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
Topics: Aged; Androgen Antagonists; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Positron-Emission Tomography; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Tumor Hypoxia | 2018 |
Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Time Factors; Tumor Hypoxia; Young Adult | 2018 |
Intracellular hypoxia measured by
Topics: Adult; Aged; Breast; Breast Neoplasms; Cell Hypoxia; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Receptors, Estrogen | 2018 |
Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging.
Topics: Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Misonidazole; Models, Theoretical; Positron-Emission Tomography; Tumor Hypoxia | 2018 |
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Topics: Adult; Aged; Cell Hypoxia; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Squamous Cell Carcinoma of Head and Neck; Tumor Hypoxia | 2019 |
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diagnostic Imaging; Disease Models, Animal; Female; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Misonidazole; Positron-Emission Tomography; Receptor, ErbB-2; Reproducibility of Results; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Accumulation of hypoxia imaging probe "
Topics: Animals; Biological Transport; Cell Hypoxia; Female; Gene Expression Regulation; Glutathione S-Transferase pi; Macrophages; Mice; Misonidazole; Molecular Imaging; Multidrug Resistance-Associated Proteins; RNA, Messenger | 2019 |
Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiation Tolerance; Radiopharmaceuticals; Tumor Hypoxia | 2019 |
Comparative evaluation of [
Topics: Animals; Autoradiography; Cell Line, Tumor; Fluorine Radioisotopes; Mice; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Radiochemistry; Reference Standards; Tissue Distribution; Tumor Hypoxia | 2019 |
Topics: Animals; Colorectal Neoplasms; Disease Models, Animal; Female; Humans; Liver Neoplasms; Mice; Misonidazole; Neoplasm Invasiveness; Positron-Emission Tomography; Radiographic Image Enhancement; Random Allocation; Sensitivity and Specificity; Xenograft Model Antitumor Assays | 2019 |
Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose-18F-fluorothymidine- 18F-fluoromisonidazole-PET/CT study and human papillomavirus status in patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Misonidazole; Papillomaviridae; Positron Emission Tomography Computed Tomography; Radioactive Tracers | 2019 |
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Topics: Adult; Aged; Cell Hypoxia; Cohort Studies; Female; Fluorine Radioisotopes; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2019 |
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
Topics: Animals; Arthritis, Experimental; Dibenzocycloheptenes; Disease Models, Animal; Glucose-6-Phosphate Isomerase; Imidazoles; Mice; Mice, Inbred BALB C; Misonidazole; Mitogen-Activated Protein Kinase 10; p38 Mitogen-Activated Protein Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines | 2019 |
Influence of the scan time point when assessing hypoxia in
Topics: Glioblastoma; Humans; Hypoxia; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Dideoxynucleosides; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Hypoxia | 2020 |
Quantification of Tumor Oxygenation Based on FMISO PET: Influence of Location and Oxygen Level of the Well-Oxygenated Reference Region.
Topics: Head and Neck Neoplasms; Humans; Misonidazole; Oximetry; Oxygen; Positron-Emission Tomography; Tumor Hypoxia; Tumor Microenvironment | 2020 |
Evaluation of non-Gaussian model-based diffusion-weighted imaging in oral squamous cell carcinoma: comparison with tumour functional information derived from positron-emission tomography.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diffusion Magnetic Resonance Imaging; Female; Humans; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2020 |
pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [
Topics: Fluorine Radioisotopes; Humans; Hydrogen-Ion Concentration; Hypoxia; Misonidazole; Molecular Structure; Positron-Emission Tomography; Signal-To-Noise Ratio | 2020 |
The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [
Topics: Animals; Astrocytes; Autoradiography; Brain; Brain Ischemia; Cerebellar Cortex; Coordination Complexes; Copper Radioisotopes; Disease Models, Animal; Fluorine Radioisotopes; Hypoxia; Male; Misonidazole; Neurons; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Thiosemicarbazones | 2021 |
Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Topics: Biliary Tract Neoplasms; Cell Hypoxia; Female; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Prospective Studies | 2021 |
18F-Fluoromisonidazole PET in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting With Tumefactive Demyelinating Lesion.
Topics: Autoantibodies; Demyelinating Diseases; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Myelin-Oligodendrocyte Glycoprotein; Positron-Emission Tomography | 2021 |
Correlation of Tumor Hypoxia Metrics Derived from
Topics: Animals; Benchmarking; Brain; Fluorescence; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Rats; Tumor Hypoxia | 2020 |
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
Topics: Adult; Aged; Bevacizumab; Biomarkers, Pharmacological; Brain Neoplasms; Cerebral Blood Volume; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Progression-Free Survival; Tumor Hypoxia; Young Adult | 2021 |
Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,
Topics: Adult; Glioblastoma; Humans; Middle Aged; Misonidazole; Positron-Emission Tomography | 2021 |
An improved one-pot preparation of [
Topics: Fluorides; Fluorine Radioisotopes; Misonidazole; Radiochemistry; Solid Phase Extraction | 2022 |
Topics: Cell Hypoxia; CTLA-4 Antigen; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2022 |
18F-FMISO PET/CT: a new promising radiotracer for cardiac sarcoidosis and extracardiac involvement?
Topics: Fluorodeoxyglucose F18; Humans; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis | 2022 |
Regional 18F-fluoromisonidazole PET images generated from multiple advanced MR images using neural networks in glioblastoma.
Topics: Bayes Theorem; Glioblastoma; Humans; Misonidazole; Neural Networks, Computer; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
Magnetic resonance imaging of hypoxia in acute stroke compared with fluorine-18 fluoromisonidazole-positron emission tomography: A cross-validation study?
Topics: Animals; Hypoxia; Ischemic Stroke; Magnetic Resonance Imaging; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Stroke | 2023 |
Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients.
Topics: Atovaquone; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Humans; Hypoxia; Lung Neoplasms; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
18 F-FMISO PET of an Intracranial Tuberculoma : A Great Mimicker.
Topics: Brain Neoplasms; Humans; Misonidazole; Positron Emission Tomography Computed Tomography; Tuberculoma, Intracranial; Tuberculosis | 2023 |
Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.
Topics: Animals; Diffusion Magnetic Resonance Imaging; Head and Neck Neoplasms; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |